Sanofi (SNY) 6-K25 Jul 242024 Q2 Condensed Half-year Consolidated Financial StatementsFinancial data

Company Profile

Cover page

Cover page	6 Months Ended
Cover page	Jun. 30, 2024
Entity Information [Line Items]
Document Type	6-K
Entity Registrant Name	SANOFI
Amendment Flag	false
Entity Central Index Key	0001121404
Current Fiscal Year End Date	--12-31
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2

Consolidated Balance Sheets

Consolidated Balance Sheets - EUR (€) € in Millions	Jun. 30, 2024		Dec. 31, 2023
Assets
Property, plant and equipment owned	€ 10,264		€ 10,160
Right-of-use assets	1,616		1,654
Goodwill	50,080		49,404
Other intangible assets	26,653		24,319
Investments accounted for using the equity method	315		424
Other non-current assets	3,333		3,218
Non-current income tax assets	129		188
Deferred tax assets	7,284		6,427
Non-current assets	99,674		95,794
Inventories	10,609		9,666
Accounts receivable	8,510		8,433
Other current assets	3,870		3,455
Current income tax assets	295		391
Cash and cash equivalents	6,795		8,710
Current assets	30,079		30,655
Assets held for sale or exchange	2		15
TOTAL ASSETS	129,755		126,464
Equity and liabilities
Equity attributable to equity holders of Sanofi	72,690		74,040
Equity attributable to non-controlling interests	307		313
Total equity	72,997		74,353
Long-term debt	12,503		14,347
Non-current lease liabilities	1,733		1,755
Non-current liabilities related to business combinations and to non-controlling interests	527	[1]	501
Non-current provisions and other non-current liabilities	8,219		7,602
Non-current income tax liabilities	1,949		1,842
Deferred tax liabilities	1,800		1,857
Non-current liabilities	26,731		27,904
Accounts payable	7,433		7,328
Current liabilities related to business combinations and to non-controlling interests	201	[1]	208
Current provisions and other current liabilities	12,746		13,741
Current income tax liabilities	132		597
Current lease liabilities	279		275
Short-term debt and current portion of long-term debt	9,236		2,045
Current liabilities	30,027		24,194
Liabilities related to assets held for sale or exchange	0		13
TOTAL EQUITY AND LIABILITIES	€ 129,755		€ 126,464

[1] As of January 1, 2024, this comprised a non-current portion of €501 million and a current portion of €208 million.

Consolidated Income Statements

Consolidated Income Statements - EUR (€) € in Millions, shares in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Profit (loss) [abstract]
Net sales	€ 21,209	€ 20,187	€ 43,070
Other revenues	1,289	1,358	3,374
Cost of sales	(6,849)	(6,347)	(14,236)
Gross profit	15,649	15,198	32,208
Research and development expenses	(3,423)	(3,193)	(6,728)
Selling and general expenses	(5,260)	(5,182)	(10,692)
Other operating income	617	617	1,292
Other operating expenses	(2,010)	(1,422)	(3,516)
Amortization of intangible assets	(1,061)	(1,035)	(2,172)
Impairment of intangible assets	371	(15)	(896)
Fair value remeasurement of contingent consideration	(66)	(26)	(93)
Restructuring costs and similar items	(1,331)	(547)	(1,490)
Other gains and losses, and litigation	(442)	(73)	(38)
Operating income	3,044	4,322	7,875
Financial expenses	(586)	(370)	(1,313)
Financial income	281	286	591
Income before tax and investments accounted for using the equity method	2,739	4,238	7,153
Income tax expense	(463)	(730)	(1,602)
Share of profit/(loss) from investments accounted for using the equity method	(13)	(52)	(115)
Net income	2,263	3,456	5,436
Net income attributable to non-controlling interests	17	26	36
Net income attributable to equity holders of Sanofi	€ 2,246	€ 3,430	€ 5,400
Average number of shares outstanding (in shares)	1,249.4	1,249.9	1,251.7
Average number of shares after dilution (in shares)	1,253.8	1,254.5	1,256.4
Basic earnings per share (in euros per share)	€ 1.80	€ 2.74	€ 4.31
Diluted earnings per share (in euros per share)	€ 1.79	€ 2.73	€ 4.30

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Statement of comprehensive income [abstract]
Net income	€ 2,263	€ 3,456	€ 5,436
Attributable to equity holders of Sanofi	2,246	3,430	5,400
Attributable to non-controlling interests	17	26	36
Other comprehensive income:
Actuarial gains/(losses)	235	141	(171)
Change in fair value of equity instruments included in financial assets and financial liabilities	(10)	3	97
Tax effects	(59)	(59)	(3)
Items not subsequently reclassifiable to profit or loss	166	85	(77)
Change in fair value of debt instruments included in financial assets	(5)	6	21
Change in fair value of cash flow hedges	(3)	1	(1)
Change in currency translation differences	1,040	(1,057)	(1,540)
Tax effects	35	(8)	(6)
Items subsequently reclassifiable to profit or loss	1,067	(1,058)	(1,526)
Other comprehensive income for the period, net of taxes	1,233	(973)	(1,603)
Comprehensive income	3,496	2,483	3,833
Attributable to equity holders of Sanofi	3,471	2,465	3,810
Attributable to non-controlling interests	€ 25	€ 18	€ 23

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - EUR (€) € in Millions		Total	Attributable to equity holders of Sanofi	Share capital	Additional paid-in capital	Treasury shares	Reserves and retained earnings	Stock options and other share-based payments	Other comprehensive income	Attributable to non-controlling interests
Beginning balance at Dec. 31, 2022		€ 75,152	€ 74,784	€ 2,522	€ 125	€ (706)	€ 66,734	€ 4,658	€ 1,451	€ 368
Other comprehensive income for the period		(973)	(965)				85		(1,050)	(8)
Net income for the period		3,456	3,430				3,430			26
Comprehensive income		2,483	2,465				3,515		(1,050)	18
Dividend paid out of earnings		(4,454)	(4,454)				(4,454)
Payment of dividends to non-controlling interests		(49)	0							(49)
Share repurchase program	[1]	(363)	(363)			(363)
Share-based payment plans:
Exercise of stock options		18	18	0	18
Issuance of restricted shares and vesting of existing restricted shares		0	0	3	(3)	112	(112)
Value of services obtained from employees		160	160					160
Tax effects of share-based payments		8	8					8
Other changes arising from issuance of restricted shares		2	2				2
Other movements (b)	[2]	(10)	9				9			(19)
Ending balance at Jun. 30, 2023		72,947	72,629	2,525	140	(957)	65,694	4,826	401	318
Beginning balance at Dec. 31, 2022		75,152	74,784	2,522	125	(706)	66,734	4,658	1,451	368
Other comprehensive income for the period		(1,603)
Net income for the period		5,436
Comprehensive income		3,833
Ending balance at Dec. 31, 2023		74,353	74,040	2,530	313	(1,184)	67,499	4,944	(62)	313
Beginning balance at Jun. 30, 2023		72,947	72,629	2,525	140	(957)	65,694	4,826	401	318
Other comprehensive income for the period		(630)	(625)				(162)		(463)	(5)
Net income for the period		1,980	1,970				1,970			10
Comprehensive income		1,350	1,345				1,808		(463)	5
Payment of dividends to non-controlling interests		(10)								(10)
Share repurchase program	[1]	(230)	(230)			(230)
Share-based payment plans:
Exercise of stock options		19	19	1	18
Employee share ownership plan		159	159	4	155
Value of services obtained from employees		123	123					123
Tax effects of share-based payments		(5)	(5)					(5)
Ending balance at Dec. 31, 2023		74,353	74,040	2,530	313	(1,184)	67,499	4,944	(62)	313
Other comprehensive income for the period		1,233	1,225				166		1,059	8
Net income for the period		2,263	2,246				2,246			17
Comprehensive income		3,496	3,471				2,412		1,059	25
Dividend paid out of earnings		(4,704)	(4,704)				(4,704)
Payment of dividends to non-controlling interests		(31)	0							(31)
Share repurchase program	[1]	(302)	(302)			(302)
Share-based payment plans:
Exercise of stock options		7	7	0	7
Issuance of restricted shares and vesting of existing restricted shares	[1]	0	0	3	(3)	115	(115)
Value of services obtained from employees		173	173					173
Tax effects of share-based payments		4	4					4
Other changes arising from issuance of restricted shares		1	1				1
Ending balance at Jun. 30, 2024		€ 72,997	€ 72,690	€ 2,533	€ 317	€ (1,371)	€ 65,093	€ 5,121	€ 997	€ 307

[1] See Note B.8.2. (for amounts relating to 2023, see Note D.1.5.4. to the consolidated financial statements for the year ended December 31, 2023). This line mainly comprises the impact on non-controlling interests arising from divestments and acquisitions.

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical) - EUR (€) € in Millions		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Dividend paid per share (in euros per share)		€ 3.76	€ 3.56
Exercise of stock options		€ 7	€ 18
Other changes arising from issuance of restricted shares		1	2
Other movements (b)	[1]		(10)
Exercise of stock options		7	18
Additional paid-in capital
Exercise of stock options		7	18
Exercise of stock options		7	18
Share capital
Exercise of stock options		0	0
Exercise of stock options		€ 0	€ 0

[1] This line mainly comprises the impact on non-controlling interests arising from divestments and acquisitions.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - EUR (€) € in Millions		6 Months Ended		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Cash flows from (used in) operating activities [abstract]
Net income attributable to equity holders of Sanofi		€ 2,246	€ 3,430	€ 5,400
Non-controlling interests		17	26	36
Share of undistributed earnings from investments accounted for using the equity method		110	196	295
Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets		1,445	1,838	4,792
Gains and losses on disposals of non-current assets, net of tax	[1]	(279)	(307)	(509)
Net change in deferred taxes		(780)	(446)	(970)
Net change in non-current provisions and other non-current liabilities	[2]	1,087	(716)	(136)
Cost of employee benefits (stock options and other share-based payments)		173	160	283
Impact of the workdown of acquired inventories remeasured at fair value		19	5	20
Other profit or loss items with no cash effect on cash flows generated by operating activities	[3]	26	196	283
Operating cash flow before changes in working capital		4,064	4,382	9,494
Adjustments to reconcile profit (loss) [abstract]
(Increase)/decrease in inventories		(886)	(1,174)	(840)
(Increase)/decrease in accounts receivable		14	(215)	(397)
Increase/(decrease) in accounts payable		82	497	402
Net change in other current assets and other current liabilities		(1,851)	73	1,599
Net cash provided by/(used in) operating activities	[4]	1,423	3,563	10,258
Cash flows from (used in) investing activities [abstract]
Acquisitions of property, plant and equipment and intangible assets		(1,886)	(930)	(3,024)
Acquisitions of consolidated undertakings and investments accounted for using the equity method	[5]	(1,885)	(2,465)	(3,870)
Acquisitions of other equity investments		(208)	(56)	(134)
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax	[6]	607	578	1,015
Disposals of consolidated undertakings and investments accounted for using the equity method		0	15	42
Net change in other non-current assets		(41)	(215)	(229)
Net cash provided by/(used in) investing activities		(3,413)	(3,073)	(6,200)
Cash flows from (used in) financing activities [abstract]
Issuance of Sanofi shares		21	31	195
Dividends paid:
Dividends paid to equity holders of Sanofi		(4,704)	(4,454)	(4,454)
Dividends paid to non-controlling interests		(31)	(49)	(61)
Payments received/(made) on changes of ownership interest in a subsidiary without loss of control		0	(3)	(3)
Additional long-term debt contracted		0	0	48
Repayments of long-term debt		(637)	(2,680)	(3,684)
Repayment of lease liabilities		(144)	(127)	(265)
Net change in short-term debt and other financial instruments	[7]	5,886	2,431	765
Acquisitions of treasury shares		(302)	(363)	(593)
Net cash provided by/(used in) financing activities		89	(5,214)	(8,052)
Impact of exchange rates on cash and cash equivalents		(14)	(19)	(32)
Net change in cash and cash equivalents		(1,915)	(4,743)	(4,026)
Cash and cash equivalents, beginning of period		8,710	12,736	12,736
Cash and cash equivalents, end of period		€ 6,795	€ 7,993	€ 8,710

[1] Includes non-current financial assets. This line item includes contributions paid to pension funds (see Note B.12.). This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items. Of which: June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) ▪ Income tax paid (1,434) (1,431) (2,623) ▪ Interest paid (320) (234) (559) ▪ Interest received 261 262 547 ▪ Dividends received from non-consolidated entities — 8 17 For the six months ended June 30, 2024, this line item includes the net cash outflow arising from the acquisition of Inhibrx, Inc. (see Note B.1.1.). For the six months ended June 30, 2023, this line includes the net cash outflow arising from the acquisition of Provention Bio Inc. For the year ended December 31, 2023, it includes the net cash outflow arising from the acquisitions of Provention Bio Inc and QRIB. This line item mainly comprises proceeds from disposals of (i) assets and businesses due to portfolio rationalization, and (ii) equity and debt instruments. For the six months ended June 30, 2024, this line mainly comprises a commercial paper program in the United States for €6,060 million, compared to €2,630 million in the six months ended June 30, 2023 and €946 million in the year ended December 31, 2023. This line also includes realized foreign exchange gains and losses on cash and cash equivalents in non-functional currencies, mainly the US dollar, and on derivatives used to manage them.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - EUR (€) € in Millions		6 Months Ended		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disclosure of detailed information about borrowings [Line Items]
Income tax paid		€ (1,434)	€ (1,431)	€ (2,623)
Interest paid		(320)	(234)	(559)
Interest received		261	262	547
Dividends received from non-consolidated entities		0	8	17
Net change in short-term debt and other financial instruments	[1]	5,886	2,431	765
Commercial paper program in USA
Disclosure of detailed information about borrowings [Line Items]
Net change in short-term debt and other financial instruments		€ 6,060	€ 2,630	€ 946

[1] For the six months ended June 30, 2024, this line mainly comprises a commercial paper program in the United States for €6,060 million, compared to €2,630 million in the six months ended June 30, 2023 and €946 million in the year ended December 31, 2023. This line also includes realized foreign exchange gains and losses on cash and cash equivalents in non-functional currencies, mainly the US dollar, and on derivatives used to manage them.

Introduction

Introduction	6 Months Ended
Introduction	Jun. 30, 2024
General Information About Financial Statements [Abstract]
Introduction	INTRODUCTION Sanofi, together with its subsidiaries (collectively “Sanofi”, “the Group” or “the Company”), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs. Sanofi is listed in Paris (Euronext: SAN) and New York (Nasdaq: SNY). The condensed consolidated financial statements for the six months ended June 30, 2024 were reviewed by the Sanofi Board of Directors at the Board meeting on July 24, 2024.

Basis of Preparation of the Hal

Basis of Preparation of the Half-Year Financial Statements and Accounting Policies	6 Months Ended
	Jun. 30, 2024
Corporate information and statement of IFRS compliance [abstract]
Basis of Preparation of the Half-Year Financial Statements and Accounting Policies	1 year: Mid Zero Coupon N/A B.10. Cross-currency swaps Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and Euronext interest rate futures > 1 year: Mid Zero Coupon N/A B.11. Liabilities related to business combinations and to non-controlling interests Fair value 3 Revenue-based approach Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11. (a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s). A.6. NEW PRONOUNCEMENTS ISSUED BY THE IASB AND APPLICABLE FROM 2025 On August 15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable from January 1, 2025 (subject to endorsement by the European Union); it will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it . On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard. On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact, and will not early adopt these amendments. On July 18, 2024, the IASB issued Volume 11 of “Annual Improvements to IFRS”, applicable from January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them." id="sjs-B4">A/ BASIS OF PREPARATION OF THE HALF-YEAR FINANCIAL STATEMENTS AND ACCOUNTING POLICIES A.1. INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS) The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS 34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023. The accounting policies used in the preparation of the consolidated financial statements as of June 30, 2024 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2024 are available via the following web link: https://www.efrag.org/Endorsement The accounting policies applied effective January 1, 2024 are identical to those presented in the consolidated financial statements for the year ended December 31, 2023. On September 22, 2022, the IASB issued an amendment to IFRS 16 (Leases) relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable from January 1, 2024 and had no impact on Sanofi's financial statements. On January 23, 2020, the IASB issued “Classification of Liabilities as Current or Non-current”, an amendment to IAS 1, and then on October 31, 2022 issued “Non-current Liabilities with Covenants”, a further amendment to IAS 1. The amendments, which are applicable from January 1, 2024, had no impact on Sanofi's financial statements. On May 25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS 7 and IFRS 7, applicable from January 1, 2024. The amendment relates to disclosures of information about such arrangements; it had no impact on the 2024 half-year financial statements . As a reminder, in its 2023 consolidated financial statements Sanofi applied “International Tax Reform – Pillar Two Model Rules”, an amendment to IAS 12 issued by the IASB on May 23, 2023, and did not recognize any deferred tax on temporary differences related to Pillar 2 rules. In its 2024 half-year financial statements, Sanofi has used an average effective tax rate that takes into account the top-up tax applicable from January 1, 2024 (see Note B.19.). A.2. USE OF ESTIMATES The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include: • amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions; • impairment of property, plant and equipment and intangible assets; • the valuation of goodwill and the valuation and useful life of acquired intangible assets; • the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable; • the measurement of financial assets and financial liabilities at amortized cost; • the amount of post-employment benefit obligations; • the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks; and • the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences. Actual results could differ from these estimates. For half-year financial reporting purposes, and as allowed under IAS 34, Sanofi has determined income tax expense on the basis of an estimate of the effective tax rate for the full financial year. That rate is applied to business operating income plus financial income and minus financial expenses, and before (i) the share of profit/loss of investments accounted for using the equity method and (ii) net income attributable to non-controlling interests. The estimated full-year effective tax rate is based on the tax rates that will be applicable to projected pre-tax profits or losses arising in the various tax jurisdictions in which Sanofi operates. A.3. SEASONAL TRENDS Sanofi’s activities are not subject to significant seasonal fluctuations. A.4. CONSOLIDATION AND FOREIGN CURRENCY TRANSLATION OF THE FINANCIAL STATEMENTS OF SUBSIDIARIES IN HYPERINFLATIONARY ECONOMIES In 2024, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met.The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial. In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July 1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level. In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January 1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level. A.5. FAIR VALUE OF FINANCIAL INSTRUMENTS Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels: • Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging); • Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and • Level 3: valuation techniques in which not all important inputs are derived from observable market data. The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments. Note Type of financial instrument Measurement principle Level in fair value hierarchy Valuation technique Method used to determine fair value Market data Valuation model Exchange rate Interest rate Volatilities B.6. Financial assets measured at fair value (quoted equity instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (quoted debt instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (unquoted equity instruments) Fair value 3 Amortized cost/ Peer comparison (primarily) If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used. B.6. Financial assets at fair value (contingent consideration receivable) Fair value 3 Revenue-based approach The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2021. B.6. Long-term loans and advances and other non-current receivables Amortized cost N/A N/A The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value. B.6. Financial assets measured at fair value held to meet obligations under post-employment benefit plans Fair value 1 Market value Quoted market price N/A B.6. Financial assets designated at fair value held to meet obligations under deferred compensation plans Fair value 1 Market value Quoted market price N/A B.9. Investments in mutual funds Fair value 1 Market value Net asset value N/A B.9. Negotiable debt instruments, commercial paper, instant access deposits and term deposits Amortized cost N/A N/A Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements. B.9. Financial Debt Amortized cost (a) N/A N/A In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments). For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections. B.9. Lease liabilities Amortized cost N/A N/A Future lease payments are discounted using the incremental borrowing rate. B.10. Forward currency contracts Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market N/A B.10. Interest rate swaps Fair value 2 Revenue-based approach Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and Euronext interest rate futures > 1 year: Mid Zero Coupon N/A B.10. Cross-currency swaps Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and Euronext interest rate futures > 1 year: Mid Zero Coupon N/A B.11. Liabilities related to business combinations and to non-controlling interests Fair value 3 Revenue-based approach Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11. (a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s). A.6. NEW PRONOUNCEMENTS ISSUED BY THE IASB AND APPLICABLE FROM 2025 On August 15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable from January 1, 2025 (subject to endorsement by the European Union); it will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it . On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard. On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact, and will not early adopt these amendments. On July 18, 2024, the IASB issued Volume 11 of “Annual Improvements to IFRS”, applicable from January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them.

Principal Changes in Scope of C

Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements	6 Months Ended
	Jun. 30, 2024
Disclosure of detailed information about business combination [abstract]
Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements	B.1. PRINCIPAL CHANGES IN SCOPE OF CONSOLIDATION IN THE PERIOD Acquisition of Inhibrx, Inc. On May 30, 2024, Sanofi completed the acquisition of Inhibrx, Inc (“ Inhibrx”), adding SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lungs with progressive tissue deterioration. SAR447537 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals. The transaction did not meet the criteria for a business combination under IFRS 3, and consequently was accounted for as an acquisition of a group of assets. The acquisition price was $2,035 million. Of that amount (plus acquisition-related costs), $1,908 million was allocated to in-process development in respect of SAR447537, and recognized within Other intangible assets in accordance with IAS 38. The difference between that amount and the acquisition price corresponds to the other assets acquired and liabilities assumed in the transaction. In addition, Sanofi awarded the former shareholders of Inhibrx an unquoted, non-negotiable Contingent Value Right (CVR) certificate that entitles them to a deferred cash payment of $5.00 per Inhibrx share, subject to attainment of a regulatory milestone before June 30, 2027. The nominal value of that commitment is $300 million. The impact of this acquisition, as reflected within the line item Acquisitions of consolidated undertakings and investments accounted for using the equity method in the consolidated statement of cash flows, is a net cash outflow of $2,035 million.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
Property, Plant and Equipment	Jun. 30, 2024
Property, plant and equipment [abstract]
Property, Plant and Equipment	B.2. PROPERTY, PLANT AND EQUIPMENT The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2024: (€ million) June 30, 2024 December 31, 2023 Acquisitions 591 1,693 Biopharma 535 1,592 Of which Manufacturing & Supply 366 1,188 Opella 56 101 Of which Manufacturing & Supply 41 90 Of which capitalized interest 22 26 Firm orders for property, plant and equipment stood at €659 million as of June 30, 2024.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
Goodwill and Other Intangible Assets	Jun. 30, 2024
Intangible assets and goodwill [abstract]
Goodwill and Other Intangible Assets	B.3. GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill amounted to €50,080 million as of June 30, 2024, versus €49,404 million as of December 31, 2023. The movement during the period was mainly due to the impact of changes in exchange rates. Movements in other intangible assets during the first half of 2024 were as follows: (€ million) Acquired R&D Products, trademarks and other rights Software Total other intangible assets Gross value at January 1, 2024 9,772 73,733 1,808 85,313 Changes in scope of consolidation (a) 1,766 — — 1,766 Acquisitions and other increases 571 201 41 813 Disposals and other decreases (49) (27) (7) (83) Currency translation differences 236 1,050 7 1,293 Transfers 2 12 (1) 13 Gross value at June 30, 2024 12,298 74,969 1,848 89,115 Accumulated amortization and impairment at January 1, 2024 (a) (3,734) (55,908) (1,352) (60,994) Amortization expense — (1,084) (52) (1,136) Impairment losses, net of reversals (b) (13) 379 — 366 Disposals and other decreases 49 27 6 82 Currency translation differences (70) (701) (4) (775) Transfers — (4) (1) (5) Accumulated amortization and impairment at June 30, 2024 (3,768) (57,291) (1,403) (62,462) Carrying amount at January 1, 2024 6,038 17,825 456 24,319 Carrying amount at June 30, 2024 8,530 17,678 445 26,653 (a) Impact of the acquisition of Inhibrx, Inc (see Note B.1.). (b) See Note B.4. Acquisitions of other intangible assets (excluding software) in the first half of 2024 totale d €772 million, including €463 million related to the agreements entered into between Sanofi and Novavax in May 2024. “Products, trademarks and other products” mainly comprise: • marketed products, with a carrying amount of €16.3 bil lion as of June 30, 2024 (versus €16.6 billion as of December 31, 2023) and a weighted average amortization period of approximately 11 years; and • technological platforms brought into service, with a carrying amou nt of €1.4 billion as of June 30, 2024 (versus €1.2 billion as of December 31, 2023 ) and a weighted average amortization period of approximately 18 years.

Impairment of Intangible Assets

Impairment of Intangible Assets	6 Months Ended
Impairment of Intangible Assets	Jun. 30, 2024
Disclosure of impairment loss and reversal of impairment loss [abstract]
Impairment of Intangible Assets	B.4. IMPAIRMENT OF INTANGIBLE ASSETS The monitoring of impairment indicators for other intangible assets led to the recognition of a net reversal of impairment losses amounting to €366 million in the first half of 2024, mainly due to an increase in the recoverable amounts of certain marketed products and other rights in the Biopharma segment.

Investments Accounted for Using

Investments Accounted for Using the Equity Method	6 Months Ended
Investments Accounted for Using the Equity Method	Jun. 30, 2024
Interests In Other Entities [Abstract]
Investments Accounted for Using the Equity Method	B.5. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2023), and comprise: (€ million) % interest June 30, 2024 December 31, 2023 EUROAPI (a) 29.8 72 162 Infraserv GmbH & Co. Höchst KG (b) 31.2 89 90 MSP Vaccine Company (c) 50.0 90 96 Other investments — 64 76 Total 315 424 (a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€2.55 as of June 30, 2024, and €5.73 as of December 31, 2023). (b) Joint venture. (c) Joint venture MSP Vaccine Company owns 100% of MCM Vaccine BV. The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below: (€ million) June 30, 2024 June 30, 2023 December 31, 2023 Sales 59 64 157 Royalties and other income 61 32 63 Accounts receivable and other receivables 278 213 249 Purchases of goods and services 345 302 642 Accounts payable and other payables 63 97 71 Subject to certain conditions, Sanofi could raise its investment in EUROAPI by €200 million in the form of a perpetual subordinated hybrid bond.

Other Non-Current Assets

Other Non-Current Assets	6 Months Ended
Other Non-Current Assets	Jun. 30, 2024
Subclassifications of assets, liabilities and equities [abstract]
Other Non-Current Assets	B.6. OTHER NON-CURRENT ASSETS Other non-current assets comprise: (€ million) June 30, 2024 December 31, 2023 Equity instruments at fair value through other comprehensive income 1,161 1,088 Debt instruments at fair value through other comprehensive income 347 346 Other financial assets at fair value through profit or loss 817 808 Pre-funded pension obligations 325 271 Long-term prepaid expenses 95 114 Long-term loans and advances and other non-current receivables 587 591 Total 3,333 3,218

Accounts Receivable

Accounts Receivable	6 Months Ended
Accounts Receivable	Jun. 30, 2024
Trade and other receivables [abstract]
Accounts Receivable	B.7. ACCOUNTS RECEIVABLE Accounts receivable break down as follows: (€ million) June 30, 2024 December 31, 2023 Gross value 8,602 8,528 Allowances (92) (95) Carrying amount 8,510 8,433 The impact of allowances against accounts receivable in the first half of 2024 was a net expense of €3 million (versus a net expense of €2 million for the first half of 2023). The table below shows the ageing profile of overdue accounts receivable, based on gross value: (€ million) Overdue accounts gross value Overdue by <1 month Overdue by 1-3 months Overdue by 3-6 months Overdue by 6-12 months Overdue by > 12 months June 30, 2024 646 264 105 137 69 71 December 31, 2023 689 269 154 123 62 81 Some Sanofi subsidiaries have assigned receivables to factoring companies or banks without recourse. The amount of receivables that met the conditions described in Note B.8.6. to the consolidated financial statements for the year ended December 31, 2023 and hence were derecognized was €503 million as of June 30, 2024 (versus €761 million as of December 31, 2023). The residual guarantees relating to those transfers were immaterial as of June 30, 2024.

Consolidated Shareholders' Equi

Consolidated Shareholders' Equity	6 Months Ended
Consolidated Shareholders' Equity	Jun. 30, 2024
Share Capital, Reserves And Other Equity Interest [Abstract]
Consolidated Shareholders' Equity	B.8. CONSOLIDATED SHAREHOLDERS’ EQUITY B.8.1. SHARE CAPITAL As of June 30, 2024, the share capital was €2,532,725,512 and consisted of 1,266,362,756 shares (the total number of shares outstanding) with a par value of €2. Treasury shares held by Sanofi are as follows: Number of shares % of share capital June 30, 2024 15.33 1.211 % December 31, 2023 13.45 1.063 % June 30, 2023 10.90 0.864 % January 1, 2023 8.20 0.650 % A total of 91,355 shares were issued in the first half of 2024 as a result of the exercise of Sanofi stock subscription options. In addition, 2,803,637 shares vested under Sanofi restricted share plans during the first half of 2024, of which 1,471,432 were fulfilled by issuance of new shares and 1,332,205 by allotment of existing shares free of charge . B.8.2. REPURCHASE OF SANOFI SHARES On May 25, 2023, the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Under that program, Sanofi repurchased 3,215,460 of its own shares during the first half of 2024 for a total amount of €302 million. On April 30, 2024 , the Annual General Meeting of Sanofi shareholders authorized a share repurchase program for a period of 18 months. Sanofi did n ot use that authorization during the first half of 2024. B.8.3. REDUCTIONS IN SHARE CAPITAL No decision to cancel treasury shares was made by the Sanofi Board of Directors during the first half of 2024. B.8.4. RESTRICTED SHARE PLANS Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2023. The principal features of the plans awarded in 2024 are set forth below: 2024 Type of plan Performance share plan Date of Board meeting approving the plan April 30, 2024 Total number of shares subject to a 3-year service period 4,505,145 Of which with no market condition 2,888,502 Fair value per share awarded (a) €81.84 Of which with market conditions 1,616,643 Fair value per share awarded other than to the Chief Executive Officer (1,394,478 shares in total) (b) €72.79 Fair value per share awarded other than to the Chief Executive Officer (139,665 additional shares) (c) €13.50 Fair value per share awarded to the Chief Executive Officer (82,500 shares) (b) €72.38 Fair value of plan at the date of grant (€ million) 346 (a) Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period. (b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period. (c) Additional tranche subject to a higher level of market conditions. The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below: June 30, 2024 June 30, 2023 Total expense for restricted share plans (€ million) 128 108 Number of shares not yet fully vested 11,192,984 10,127,545 Under 2024 plans 4,498,109 — Under 2023 plans 3,652,352 3,837,974 Under 2022 plans 3,031,060 3,226,321 Under 2021 plans 11,463 2,996,101 Under 2020 plans — 67,149 B.8.5. CAPITAL INCREASES On January 31, 2024, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of €72.87 per share. The subscription period was open from June 4 through June 24, 2024. Sanofi employees subscribed for a total of 2,124,445 shares, and this capital increase was supplemented by the immediate issuance of a further 119,951 shares for the employer’s contribution. The total expense recognized for this capital increase in the first half of 2024 was €45 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees. On February 2, 2023, the Sanofi Board of Directors approved a capital increase reserved for employees, offering the opportunity for them to subscribe for new Sanofi shares at a price of €79.58 per share. The subscription period was open from June 5 through June 23, 2023. Sanofi employees subscribed for a total of 2,009,306 shares, and this capital increase was supplemented by the immediate issuance of a further 119,417 shares for the employer’s contribution. The total expense recognized for this capital increase in the first half of 2023 was €52 million, determined in accordance with IFRS 2 (Share-Based Payment) on the basis of the discount granted to the employees. B.8.6. STOCK SUBSCRIPTION OPTION PLANS No stock subscription option plans were awarded in the first half of 2024 or in 2023. No more expenses have been recognized through equity for stock option plans in either 2024 or 2023. The table below provides summary information about options outstanding and exercisable as of June 30, 2024: Range of exercise prices per share Outstanding Exercisable Number of options Weighted average residual life (years) Weighted average exercise price per share (€) Number of options Weighted average exercise price per share (€) From €60.00 to €70.00 per share 168,784 3.84 65.84 168,784 65.84 From €70.00 to €80.00 per share 478,150 3.18 76.26 478,150 76.26 From €80.00 to €90.00 per share 594,724 1.79 89.20 594,724 89.20 Total 1,241,658 1,241,658 B.8.7. NUMBER OF SHARES USED TO COMPUTE DILUTED EARNINGS PER SHARE Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares. (million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Average number of shares outstanding 1,249.4 1,249.9 1,251.7 Adjustment for stock options with dilutive effect 0.1 0.3 0.2 Adjustment for restricted shares 4.3 4.3 4.5 Average number of shares used to compute diluted earnings per share 1,253.8 1,254.5 1,256.4 As of June 30, 2024, December 31, 2023 and June 30, 2023 all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. B.8.8. OTHER COMPREHENSIVE INCOME Movements within other comprehensive income are shown below: (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Actuarial gains/(losses): ▪ Actuarial gains/(losses) excluding investments accounted for using the equity method 235 133 (171) ▪ Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes — 8 — ▪ Tax effects (57) (60) 18 Equity instruments included in financial assets and financial liabilities: — — — ▪ Change in fair value (excluding investments accounted for using the equity method) (10) 3 97 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — — — ▪ Equity risk hedging instruments designated as fair value hedges — — — ▪ Tax effects (2) 1 (21) Items not subsequently reclassifiable to profit or loss 166 85 (77) Debt instruments included in financial assets: ▪ Change in fair value (excluding investments accounted for using the equity method) (a) (5) 6 21 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — — — ▪ Tax effects 1 (1) (4) Cash flow hedges and fair value hedges: ▪ Change in fair value (excluding investments accounted for using the equity method) (b) (4) 1 1 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) 1 — (2) ▪ Tax effects 1 — — Change in currency translation differences: ▪ Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method) (c) 1,167 (1,089) (1,551) ▪ Currency translation differences (investments accounted for using the equity method) (1) 6 3 ▪ Hedges of net investments in foreign operations (126) 26 8 ▪ Tax effects 33 (7) (2) Items subsequently reclassifiable to profit or loss 1,067 (1,058) (1,526) (a) Includes reclassifications to profit or loss: immaterial over all periods. (b) Includes reclassifications to profit or loss: immaterial over all periods. (c) Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar. Includes a reclassification to profit or loss: immaterial in the first half of 2024 , €(56) million in 2023 and €(14) million in the first half of 2023.
Summary of Treasury Shares Held	B.8. CONSOLIDATED SHAREHOLDERS’ EQUITY B.8.1. SHARE CAPITAL As of June 30, 2024, the share capital was €2,532,725,512 and consisted of 1,266,362,756 shares (the total number of shares outstanding) with a par value of €2. Treasury shares held by Sanofi are as follows: Number of shares % of share capital June 30, 2024 15.33 1.211 % December 31, 2023 13.45 1.063 % June 30, 2023 10.90 0.864 % January 1, 2023 8.20 0.650 % A total of 91,355 shares were issued in the first half of 2024 as a result of the exercise of Sanofi stock subscription options. In addition, 2,803,637 shares vested under Sanofi restricted share plans during the first half of 2024, of which 1,471,432 were fulfilled by issuance of new shares and 1,332,205 by allotment of existing shares free of charge .

Debt, Cash and Cash Equivalents

Debt, Cash and Cash Equivalents	6 Months Ended
Debt, Cash and Cash Equivalents	Jun. 30, 2024
Cash and cash equivalents [abstract]
Debt, Cash and Cash Equivalents	B.9. DEBT, CASH AND CASH EQUIVALENTS Changes in financial position during the period were as follows: (€ million) June 30, 2024 December 31, 2023 Long-term debt 12,503 14,347 Short-term debt and current portion of long-term debt 9,236 2,045 Interest rate and currency derivatives used to manage debt 179 139 Total debt 21,918 16,531 Cash and cash equivalents (6,795) (8,710) Interest rate and currency derivatives used to manage cash and cash equivalents (11) (28) Net debt (a) 15,112 7,793 (a) Net debt does not include lease liabilities, which amounted to €2,012 million as of June 30, 2024 and €2,030 million as of December 31, 2023. “Net debt” is a financial indicator used by management and investors to measure Sanofi’s overall net indebtedness. B.9.1. NET DEBT AT VALUE ON REDEMPTION A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2024 is shown below: (€ million) Value on redemption Carrying amount at June 30, 2024 Amortized cost Adjustment to debt measured at fair value June 30, 2024 December 31, 2023 Long-term debt 12,503 35 150 12,688 14,546 Short-term debt and current portion of long-term debt 9,236 — 18 9,254 2,045 Interest rate and currency derivatives used to manage debt 179 — (169) 10 (18) Total debt 21,918 35 (1) 21,952 16,573 Cash and cash equivalents (6,795) — — (6,795) (8,710) Interest rate and currency derivatives used to manage cash and cash equivalents (11) — — (11) (28) Net debt (a) 15,112 35 (1) 15,146 7,835 (a) Net debt does not include lease liabilities, which amounted to €2,012 million as of June 30, 2024 and €2,030 million as of December 31, 2023. The table below shows an analysis of net debt by type, at value on redemption: (€ million) June 30, 2024 December 31, 2023 non-current current Total non-current current Total Bond issues 12,593 1,916 14,509 14,416 718 15,134 Other bank borrowings 95 7,118 (a) 7,213 130 1,118 1,248 Other borrowings — 5 5 — 6 6 Bank credit balances — 215 215 — 203 203 Interest rate and currency derivatives used to manage debt — 10 10 — (18) (18) Total debt 12,688 9,264 21,952 14,546 2,027 16,573 Cash and cash equivalents — (6,795) (6,795) — (8,710) (8,710) Interest rate and currency derivatives used to manage cash and cash equivalents — (11) (11) — (28) (28) Net debt 12,688 2,458 15,146 14,546 (6,711) 7,835 (a) As of June 30, 2024, current other bank borrowings includ e €6,955 million related to the US Commercial Paper program and €0 million related to the Negotiable European Commercial Paper program in France. Principal financing and debt reduction transactions during the period Sanofi did not carry out any bond issues in the first half of 2024. An April 2016 fixed-rate bond issue of €600 million, which matured on April 5, 2024, was redeemed during the first half of 2024. As of June 30, 2024, Sanofi had two syndicated credit facilities linked to social and environmental criteria in place to manage its liquidity in connection with current operations: i. a syndicated credit facility of €4 billion, drawable in euros and US dollars and expiring on December 6, 2027, for which no further extension options are available; and ii. a syndicated credit facility of €4 billion, drawable in euros and US dollars and expiring on March 7, 2029, for which a further one-year extension option remains available. As of June 30, 2024, neither facility was drawn down. Sanofi also has two short-term debt programs: i. a €6 billion Negotiable European Commercial Paper program in France; and ii. a $10 billion Commercial Paper program in the United States. During the first half of 2024: i. the average drawdown under the US Commercial Paper program was $5.8 billion; and ii. the average drawdown under the Negotiable European Commercial Paper program in France was €0.1 billion. The financing in place as of June 30, 2024 at the level of the holding company (which manages most of Sanofi’s financing needs centrally) is not subject to any financial covenants, and contains no clauses linking credit spreads or fees to the credit rating. B.9.2. MARKET VALUE OF NET DEBT The market value of Sanofi’s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows: (€ million) June 30, 2024 December 31, 2023 Market value 14,214 7,086 Value on redemption 15,146 7,835

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
Derivative Financial Instruments	Jun. 30, 2024
Financial Instruments [Abstract]
Derivative Financial Instruments	B.10. DERIVATIVE FINANCIAL INSTRUMENTS B.10.1 CURRENCY DERIVATIVES USED TO MANAGE OPERATING RISK EXPOSURES The table below shows operating currency hedging instruments in place as of June 30, 2024. The notional amount is translated into euros at the relevant closing exchange rate. June 30, 2024 Of which derivatives designated as cash flow hedges Of which derivatives not eligible for hedge accounting (€ million) Notional amount Fair value Notional amount Fair value Of which recognized in equity Notional amount Fair value Forward currency sales 5,120 (45) — — — 5,120 (45) of which US dollar 2,152 (17) — — — 2,152 (17) of which Chinese yuan renminbi 608 — — — — 608 — of which Russian rouble 252 (31) — — — 252 (31) of which Japanese yen 269 5 — — — 269 5 of which Singapore dollar 197 (1) — — — 197 (1) Forward currency purchases 3,195 21 — — — 3,195 21 of which US dollar 1,733 2 — — — 1,733 2 of which Singapore dollar 398 1 — — — 398 1 of which Russian rouble 203 12 — — — 203 12 of which Turkish lira 108 7 — — — 108 7 of which Canadian dollar 100 1 — — — 100 1 Total 8,315 (24) — — — 8,315 (24) The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June 30, 2024 and recognized in the balance sheet at that date. Gains and losses on hedging in struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of 2024 . B.10.2. CURRENCY AND INTEREST RATE DERIVATIVES USED TO MANAGE FINANCIAL EXPOSURE The cash pooling arrangements for foreign subsidiaries outside the eurozone, and some of Sanofi’s financing activities, expose certain Sanofi entities to financial foreign exchange risk (i.e. the risk of changes in the value of loans and borrowings denominated in a currency other than the functional currency of the lender or borrower). That foreign exchange exposure is hedged using derivative instruments (currency swaps or forward contracts) that alter the currency split of Sanofi’s debt once those instruments are taken into account. The table below shows financial currency hedging instruments in place as of June 30, 2024. The notional amount is translated into euros at the relevant closing exchange rate. June 30, 2024 (€ million) Notional amount Fair value Maximum expiry date Forward currency sales 7,190 (30) of which US dollar 5,797 (a) (28) 2024 of which Chinese yuan renminbi 301 (1) 2024 of which Canadian dollar 190 (1) 2024 Forward currency purchases 7,656 42 of which US dollar 5,242 (b) (c) 37 2025 of which Singapore dollar 1,768 7 2024 of which Hungarian forint 182 (1) 2024 Total 14,846 12 (a) Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi’s net investment in Bioverativ. As of June 30, 2024, the fair value of these forward contracts represented a liability of €26 million; the opposite entry was recognized in “Other comprehensive income”, with the impact on financial income and expense being immaterial. (b) Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2024, the fair value of these contracts represented an asset of €2 million, with €0 million credited to “Other comprehensive income” to recognize the hedging cost. (c) Includes forward purchases with a notional amount of $1,080 million expiring in 2024 , designated as a fair value hedge of $1,080 million of commercial paper. As of June 30, 2024, the fair value of these contracts represented an asset of €16 million, with €0 million credited to “Other comprehensive income” to recognize the hedging cost. . To optimize the cost of debt or reduce the volatility of debt, Sanofi uses derivative instruments (interest rate swaps and cross currency swaps) to alter the fixed/floating rate split of its net debt. The table below shows instruments of this type in place as of June 30, 2024: Of which designated as fair value hedges Of which designated as cash flow hedges (€ million) 2024 2025 2026 2027 2028 and beyond Total Fair value Notional amount Fair value Notional amount Fair value Of which recognized in equity Interest rate swaps pay capitalized SOFR USD / receive 1.02% — — — — 467 467 (53) 467 (53) — — — pay capitalized SOFR USD / receive 1.32% — — — — 467 467 (48) 467 (48) — — — pay capitalized Ester / receive 0.69% — 850 — — — 850 (24) 850 (24) — — — pay capitalized Ester / receive 0.92% — — — — 650 650 (56) 650 (56) — — — pay capitalized Ester / receive 3.56% 997 — — — — 997 — 997 — — — — Total 997 850 — — 1,584 3,431 (181) 3,431 (181) — — —

Non-Current Provisions And Othe

Non-Current Provisions And Other Non-Current Liabilities	6 Months Ended
Non-Current Provisions And Other Non-Current Liabilities	Jun. 30, 2024
Subclassifications of assets, liabilities and equities [abstract]
Non-Current Provisions And Other Non-Current Liabilities	B.12. NON-CURRENT PROVISIONS AND OTHER NON-CURRENT LIABILITIES The line item Non-current provisions and other non-current liabilities comprises the following: (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Provisions 5,918 5,018 5,262 Other non-current liabilities (a) 2,301 2,070 2,340 Total 8,219 7,088 7,602 (a) Includes €1,970 million at June 30, 2024 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States. Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is €1,147 million; the nominal value of payments estimated to be due after more than five years is €2,679 million. The table below shows movements in provisions: (€ million) Provisions for pensions & other post-employment benefits Provisions for other long-term benefits Restructuring provisions Other provisions Total Balance at January 1, 2024 2,214 718 554 1,776 5,262 Increases in provisions and other liabilities 72 (a) 89 581 559 1,301 Provisions utilized (78) (a) (65) (11) (76) (230) Reversals of unutilized provisions (63) (a) 1 (4) (53) (119) Transfers (b) 75 — (173) (24) (122) Net interest related to employee benefits, and unwinding of discount 37 3 9 11 60 Currency translation differences 18 13 (47) 17 1 Actuarial gains and losses on defined-benefit plans (B.12.1.) (235) — — — (235) Balance at June 30, 2024 2,040 759 909 2,210 5,918 (a) In the case of “Provisions for pensions and other post-employment benefits”, the “Increases in provisions” line corresponds to rights vesting in employees during the period, and past service cost; the “Provisions utilized” line corresponds to contributions paid into pension funds and to beneficiaries; and the “Reversals of unutilized provisions” line corresponds to plan curtailments, settlements and amendments. (b) Mainly transfers to the line “Current provisions and other current liabilities”. Provisions for pensions and other post-employment benefits For an analysis of the sensitivity of obligations in respect of pensions and other employee benefits as of December 31, 2023, and of the assumptions used as of that date, see Note D.19.1. to the consolidated financial statements for the year ended December 31, 2023. The principal assumptions used (in particular, changes in discount and inflation rates and in the market value of plan assets) for the eurozone, the United States and the United Kingdom were reviewed as of June 30, 2024 to take into account changes during the first half of the year. Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax): (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Actuarial gains/(losses) on plan assets (138) 34 (208) Actuarial gains/(losses) on benefit obligations 373 (a) 99 (b) 379 (a) Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the change in the inflation rate in the United Kingdom (+0.10%) in the first half of 2024. (b) Includes the effects of (i) the change in discount rates (in a range between -0.15% and +0.40%) and (ii) the change in the inflation rate in the eurozone (-0.10%) in the first half of 2023.

Off Balance Sheet Commitments

Off Balance Sheet Commitments	6 Months Ended
Off Balance Sheet Commitments	Jun. 30, 2024
Off-Balance Sheet Commitments [Abstract]
Off Balance Sheet Commitments	B.13. OFF BALANCE SHEET COMMITMENTS Off balance sheet commitments to third parties as of December 31, 2023 are presented in Note D.21.1. to the consolidated financial statements for the year ended December 31, 2023. The principal commitments entered into, amended or discontinued during the period are described below: • On May, 2024, Sanofi entered into a co-exclusive licensing agreement with Novavax. The terms of the agreement include (i) a co-exclusive license to co-commercialize Novavax’s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea, where Novavax has existing partnership agreements); (ii) a sole license to Novavax’s adjuvanted COVID-19 vaccine for use in combination with Sanofi’s flu vaccines; and (iii) a non-exclusive license to use the Matrix-M adjuvant in vaccine products. Novavax received an upfront payment of $500 million and up to $700 million in development, regulatory and launch milestones, representing up to $1.2 billion in total. Starting in 2025, Sanofi will book sales of Novavax’s adjuvanted COVID-19 vaccine and will support certain R&D, regulatory, and commercial expenses. Novavax will receive double-digit tiered royalties on sales of COVID-19 vaccines and combined influenza/COVID-19 vaccines made by Sanofi. Novavax is also entitled to additional launch and sales milestones opportunities of up to $200 million, plus single-digit royalties for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax’s Matrix-M adjuvant technology. In addition, Sanofi took a minority (<5%) equity investment in Novavax. This agreement will provide patients with broader access from 2025 onwards to a protein-based non-mRNA adjuvanted COVID-19 vaccine. Outside of the collaboration, each party may develop and commercialize their own flu and COVID-19 vaccines and their own adjuvanted products at their own cost. ▪ On May, 2024, Sanofi entered into a collaboration and license agreement with Fulcrum Therapeutics for the development and commercialization of losmapimod, an investigational oral therapy for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The agreement combines Fulcrum’s FSHD expertise with Sanofi’s global reach and commitment to treating people with rare diseases. Under the terms of the agreement, Sanofi obtained exclusive commercialization rights outside of the United States, while Fulcrum retained the US rights. Fulcrum will receive an upfront payment of $80 million, and could receive up to $975 million contingent on the attainment of specified milestones, plus royalties on non-US sales. The two parties will share worldwide development costs equally. Losmapimod, currently in worldwide Phase 3 clinical trials, has demonstrated promising results in slowing the progression of FSHD; data from the Phase 3 trial are expected by end 2024. If the results are positive, Fulcrum and Sanofi intend to file for marketing approval in the United States, Europe, Japan, and other regions. Sanofi has also entered into power purchase agreements in furtherance of its ESG strategy. The characteristics of the principal power purchase agreements in place as of June 30, 2024 are summarized below: Country Type of Energy Annual Volume Start Date Term Type of Contract Accounting Treatment France Solar 8 GWh 2025 20 years PPA (a) Own use procurement contracts (b) Wind 46 GWh 2025 20 years Wind 29 GWh 2025 20 years (a) Power Purchase Agreement (PPA): long-term renewable energy contract resulting in physical supply of electricity. (b) At the current stage of analysis, with reference to the own use exception permitted by paragraph 2.4 of IFRS 9. These contracts help secure the objective of 100% green electricity supply across all operations of the Group by 2030.

Litigation and Arbitration Proc

Litigation and Arbitration Proceedings	6 Months Ended
Litigation and Arbitration Proceedings	Jun. 30, 2024
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Litigation and Arbitration Proceedings	B.14. LITIGATION AND ARBITRATION PROCEEDINGS Sanofi and its affiliates are involved in litigation, arbitration and other legal proceedings. These proceedings typically are related to product liability claims, intellectual property rights (particularly claims against generic companies seeking to limit the patent protection of Sanofi products), competition law and trade practices, commercial claims, employment and wrongful discharge claims, tax assessment claims, waste disposal and pollution claims, and claims under warranties or indemnification arrangements relating to business divestitures. The matters discussed below constitute the most significant developments since publication of the financial statements for the year ended December 31, 2023. B.14.1. PRODUCTS TAXOTERE PRODUCT LITIGATION IN THE US As of June 30, 2024, there were approximately 6,770 ingesting plaintiffs cases remaining in courts across the country. Throughout the first half of 2024, Sanofi entered into a number of settlement agreements or agreements in principle with many plaintiffs’ firms encompassing nearly all the remaining cases. These agreements require the consent of the individual plaintiffs and will take some time to conclude, in order to ensure that certain threshold participation requirements are met. ZANTAC PRODUCT LITIGATION IN THE US In March 2024, Sanofi reached agreement in principle with a number of plaintiffs’ lawyers to resolve Zantac personal injury cases pending against it in all US state courts outside of Delaware. This agreement would resolve approximately 75% of nearly 4,400 cases. The agreement requires the consent of individual plaintiffs and will take some time to conclude. In the State court cases pending in Delaware, the State of Delaware court decided in May 2024 not to exclude plaintiffs’ experts from the cases. Sanofi is appealing this decision. GOLD BOND PRODUCT LITIGATION IN THE US As of June 30, 2024, Sanofi is named as a defendant in approximately 600 product liability ongoing actions. DEPAKINE PRODUCT LITIGATION IN FRANCE Civil Proceedings Several questions on the Product Liability Directive have been referred to the European Court of Justice (ECJ), which will have an impact on the pending Depakine cases. A ruling from the ECJ is expected between September and December 2025. As a result, several stays in the proceedings have been requested including in the class action, the anxiety damage claim, and several individual proceedings. Similar requests will be made in the remaining proceedings (in particular, on appeal), depending on the timescales determined by the Courts. In the class action, a hearing is scheduled for September 2024 for this question to be tried. As regards the anxiety damage cases, the ruling is expected on August 2, 2024. DENGVAXIA PRODUCT LITIGATION IN THE PHILIPPINES On July 16, 2024, the Court dismissed the first eight criminal cases, ruling the prosecution failed to establish the elements of “reckless imprudence” resulting in homicide. Remaining cases are still pending at various stages. B.14.2. PATENTS PRALUENT (alirocumab)-RELATED AMGEN PATENT LITIGATION IN EUROPE In the revocation action filed by Sanofi against Amgen before the Munich Central Division of the Unified Patent Court, a decision on the Amgen patent’s validity was issued on July 16, 2024. This decision revokes Amgen’s patent, hence supporting Sanofi/Regeneron’s position. The decision can be appealed. Sanofi and Regeneron have also attacked the validity of the same EP 3 666 797 patent at the European Patent Office. These proceedings are ongoing. B.14.3. OTHER LITIGATION PLAVIX (clopidogrel) - ATTORNEY GENERAL ACTION IN HAWAII On May 21, 2024, the Court issued a new decision against Sanofi and BMS, imposing penalties in the total amount of $916 million, with $458 million attributed to Sanofi. Sanofi and BMS will appeal the decision. PLAVIX (clopidogrel)-RELATED LITIGATION IN FRANCE In the claim filed by the CNAM, the final expert report was issued in March 2024. 340B DRUG PRICING PROGRAM IN THE UNITED STATES In May 2024, Sanofi filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA) under the Freedom of Information Act (FOIA) seeking an order declaring that Sanofi is entitled to covered entities’ pharmacy contracts, requiring HRSA to produce the contracts and enjoining HRSA from withholding pharmacy contracts from Sanofi pursuant to its FOIA request. Mosaic Health in the United States In February 2024, plaintiffs filed a notice of appeal of the dismissal of the complaint by the Court. Adventist Health System/West in the United States

Other Operating Income And Expe

Other Operating Income And Expenses	6 Months Ended
Other Operating Income And Expenses	Jun. 30, 2024
Analysis of income and expense [abstract]
Other Operating Income and Expenses	B.15. OTHER OPERATING INCOME AND EXPENSES Other operating income amounted to €617 million in the first half of 2024 (versus €617 million in the first half of 2023), and Other operating expenses to €2,010 million (versus € 1,422 million in the first half of 2023). The main items included in Other operating income were: in the first half of 2024, (i) income from pharmaceutical partners of €118 million (versus €160 million in the first half of 2023), of which €96 million came from Regeneron (versus €102 million in the first half of 2023, see table below) and (ii) gains on disposals of assets and operations of €389 million, primarily on divestments of non strategic products (versus €413 million in the first half of 2023). Other operating expenses for the first half of 2024 included €1,841 million of expenses related to Regeneron (compared with €1,423 million in the first half of 2023), as shown in the table below. (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance (1,934) (1,449) (3,321) Additional share of profit paid by Regeneron towards development costs 389 291 668 Reimbursement to Regeneron of selling expenses incurred (292) (260) (543) Total: Monoclonal Antibody Alliance (1,837) (1,418) (3,196) Other (mainly Zaltrap and Libtayo) 92 97 217 Other operating income/(expenses), net related to Regeneron (1,745) (1,321) (2,979) of which amount presented in “Other operating income” 96 102 227

Restructuring Costs and Similar

Restructuring Costs and Similar Items	6 Months Ended
Restructuring Costs and Similar Items	Jun. 30, 2024
Analysis of income and expense [abstract]
Restructuring Costs and Similar Items	B.16. RESTRUCTURING COSTS AND SIMILAR ITEMS Restructuring costs and similar items comprise the following: (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Employee-related expenses 849 185 489 Charges, gains or losses on assets (a) (31) 86 293 Costs of transformation programs 347 265 676 Other restructuring costs 166 11 32 Total 1,331 547 1,490 (a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi. Restructuring and similar costs increased by €784 million between June 30, 2023 and June 30, 2024. They mainly comprise costs relating to severance plans announced in the first half of 2024. For the six months ended June 30, 2023 and the year ended December 31, 2023, they included the impact of pension reform in France on future annuities under the rules of each severance plan. Restructuring costs also include Sanofi's ongoing transformation projects, mainly those relating to the separation of the Opella business.

Other Gains and Losses, and Lit

Other Gains and Losses, and Litigation	6 Months Ended
Other Gains and Losses, and Litigation	Jun. 30, 2024
Analysis of income and expense [abstract]
Other Gains and Losses, and Litigation	B.17. OTHER GAINS AND LOSSES, AND LITIGATION For the first half of 2024, Other gains and losses, and litigation is a charge of €442 million, mainly comprising a provision recognized in respect of the litigation related to Plavix (clopidogrel) in the US state of Hawaii (see note B.14.) . That compares with a charge of €73 million in the first half of 2023, which comprised costs related to the settlement of a dispute with shareholders of Bioverativ.

Financial Expenses and Income

Financial Expenses and Income	6 Months Ended
Financial Expenses and Income	Jun. 30, 2024
Analysis of income and expense [abstract]
Financial Expenses and Income	B.18. FINANCIAL EXPENSES AND INCOME An analysis of financial expenses and income is set forth below: (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Cost of debt (a) (309) (232) (555) Interest income (b) 243 257 533 Cost of net debt (66) 25 (22) Non-operating foreign exchange gains/(losses) 1 (3) (2) Unwinding of discounting of provisions (c) (17) (22) (59) Net interest cost related to employee benefits (40) (41) (73) Gains/(losses) on disposals of financial assets — — (1) Net interest expense on lease liabilities (22) (21) (39) Other (d) (161) (22) (526) Net financial income/(expenses) (305) (84) (722) comprising: Financial expenses (586) (370) (1,313) Financial income 281 286 591 (a) Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: €(24) million in the first half of 2024, €(25) million in the first half of 2023, and €(67) million over the whole of 2023. (b) Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: €(18) million in the first half of 2024, €(4) million in the first half of 2023, and €(13) million over the whole of 2023. (c) Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.). (d) Includes a financial expense of €176 million for the six months ended June 30, 2024 (€541 million for the year ended December 31, 2023, €35 million for the six months ended June 30, 2023) for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US. The impact of the ineffective portion of hedging relationships was not material in either 2024 or 2023.

Income Tax Expense

Income Tax Expense	6 Months Ended
Income Tax Expense	Jun. 30, 2024
Income taxes paid (refund) [abstract]
Income Tax Expense	B.19. INCOME TAX EXPENSE Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States. The table below shows the allocation of income tax expense between current and deferred taxes: (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Current taxes (1,243) (1,171) (2,560) Deferred taxes 780 441 958 Total (463) (730) (1,602) Income before tax and investments accounted for using the equity method 2,739 4,238 7,153 The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows: (as a percentage) June 30, 2024 (6 months) (a) June 30, 2023 (6 months) (a) December 31, 2023 (12 months) Standard tax rate applicable in France 25.8 25.8 25.8 Difference between the standard French tax rate and the rates applicable to Sanofi (b) (14.3) (8.2) (13.6) Probable reversal of temporary differences on investments in Opella subsidiaries (c) — — 5.1 Revisions to tax exposures and settlements of tax disputes 3.2 0.5 2.7 Fair value remeasurement of contingent consideration liabilities — — 0.1 Other (d) 2.2 (0.8) 2.3 Effective tax rate 16.9 17.3 22.4 (a) Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.). (b) The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France. (c) In accordance with IAS12, a deferred tax liability was recognised in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Opella business, as announced in October 2023. (d) For the six months ended June 30, 2024, this line includes a tax expense of €52 million, representing the estimated impact of Pillar 2 based on Sanofi’s current understanding of Pillar Two rules.

Segment Information

Segment Information	6 Months Ended
Segment Information	Jun. 30, 2024
Disclosure of operating segments [abstract]
Segment Information	B.20. SEGMENT INFORMATION Sanofi reports two operating segments: Biopharma and Opella (formerly Consumer Healthcare – CHC). The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment’s results include the costs of global support functions that are not within the managerial responsibility of the Opella GBU. The Opella operating segment comprises commercial operations relating to consumer healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Opella GBU segment’s results reflect all incurred costs of global support functions attributable to its business. The “Other” category comprises reconciling items, primarily but not limited to (i) gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii) gains and losses on retained commitments in respect of previously divested operations. B.20.1. SEGMENT RESULTS B.20.1.1. Analysis of net sales The table below sets forth net sales for the six months ended June 30, 2024 and June 30, 2023: (€ million) Europe United States Other June 30, 2024 Europe United Other June 30, 2023 Total Biopharma 4,074 8,294 6,010 18,378 4,194 7,366 5,907 17,467 Total Pharma 3,692 7,550 4,817 16,059 3,624 6,709 4,744 15,077 Dupixent 770 4,437 931 6,138 587 3,682 609 4,878 Total Pharma launches 249 868 178 1,295 168 460 87 715 of which Nexviazyme 95 174 51 320 42 123 19 184 Sarclisa 64 100 63 227 56 76 49 181 ALTUVIIIO — 259 21 280 — 17 2 19 Rezurock 12 188 7 207 2 140 (1) 141 Cablivi 43 60 10 113 49 58 6 113 Xenpozyme 24 37 11 72 15 21 2 38 Enjaymo 10 30 15 55 4 19 10 33 Tzield 1 20 — 21 — 6 — 6 Total other products 2,673 2,245 3,708 8,626 2,869 2,567 4,048 9,484 of which Industrial sales 274 3 1 278 264 3 13 280 Total Vaccines 382 744 1,193 2,319 570 657 1,163 2,390 of which Influenza Vaccines 30 16 142 188 37 19 106 162 Polio/Pertussis/ 248 311 789 1,348 231 347 850 1,428 RSV vaccines (Beyfortus) 7 116 77 200 — — — — Meningitis, travel and endemics vaccines 97 301 184 582 72 291 206 569 Total Opella 808 773 1,250 2,831 840 622 1,258 2,720 of which Seasonal symptoms & pain relief 1,216 1,261 Wellness brands 1,258 1,112 Others 357 347 Total net sales 4,882 9,067 7,260 21,209 5,034 7,988 7,165 20,187 B.20.1.2. Business operating income Sanofi reports segment results on the basis of “Business operating income”, a non-IFRS financial measure used internally by the chief operating decision maker to measure the performance of each operating segment and to allocate resources. “Business operating income” is derived from Operating income , adjusted as follows: • the amounts reported in the line items Restructuring costs and similar items, Fair value remeasurement of contingent consideration relating to business combinations (IFRS 3) or divestments and Other gains and losses, and litigation are eliminated; • expenses arising from the remeasurement of inventories following a business combination (IFRS 3) are eliminated; • amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature) are eliminated; • the share of profits/losses from investments accounted for using the equity method is added for joint ventures and associates with which Sanofi has entered into a strategic partnership agreement; and • net income attributable to non-controlling interests is deducted. Segment results are shown in the table below: June 30, 2024 (6 months) (€ million) Biopharma Opella Other (a) Total Net sales 18,378 2,831 — 21,209 Other revenues 1,257 32 — 1,289 Cost of sales (5,756) (1,077) 3 (6,830) Research and development expenses (3,331) (92) — (3,423) Selling and general expenses (4,260) (1,002) 2 (5,260) Other operating income and expenses (1,417) 43 (19) (1,393) Share of profit/(loss) from investments accounted for using the equity method 66 9 — 75 Net income attributable to non-controlling interests (6) (5) — (11) Business operating income 4,931 739 (14) 5,656 (a) The “Other” column reconciles segmental results to the total per the consolidated financial statements. . June 30, 2023 (6 months) (€ million) Biopharma Opella Other (a) Total Net sales 17,467 2,720 — 20,187 Other revenues 1,331 27 — 1,358 Cost of sales (5,388) (949) (5) (6,342) Research and development expenses (3,082) (111) — (3,193) Selling and general expenses (4,248) (936) 2 (5,182) Other operating income and expenses (897) 100 (8) (805) Share of profit/(loss) from investments accounted for using the equity method 48 7 — 55 Net income attributable to non-controlling interests (11) (8) — (19) Business operating income 5,220 850 (11) 6,059 (a) The “Other” column reconciles segmental results to the total per the consolidated financial statements. December 31, 2023 (12 months) (€ million) Biopharma Opella Other (a) Total Net sales 37,890 5,180 — 43,070 Other revenues 3,322 52 — 3,374 Cost of sales (12,282) (1,933) (1) (14,216) Research and development expenses (6,509) (219) — (6,728) Selling and general expenses (8,868) (1,828) 4 (10,692) Other operating income and expenses (2,387) 181 (18) (2,224) Share of profit/(loss) from investments accounted for using the equity method 101 21 — 122 Net income attributable to non-controlling interests (20) (16) — (36) Business operating income 11,247 1,438 (15) 12,670 (a) The “Other” column reconciles segmental results to the total per the consolidated financial statements. The table below, presented in compliance with IFRS 8, shows a reconciliation between “Business operating income” and Income before tax and investments accounted for using the equity method : (€ million) June 30, 2024 ( 6 months) June 30, 2023 ( 6 months) December 31, 2023 (12 months) Business operating income 5,656 6,059 12,670 Share of profit/(loss) from investments accounted for using the equity method (a) (75) (55) (122) Net income attributable to non-controlling interests (b) 11 19 36 Amortization and impairment of intangible assets (c) (690) (1,050) (3,068) Fair value remeasurement of contingent consideration (66) (26) (93) Expense arising from the impact of acquisitions on inventories (d) (19) (5) (20) Restructuring costs and similar items (e) (1,331) (547) (1,490) Other gains and losses, and litigation (f) (442) (73) (38) Operating income 3,044 4,322 7,875 Financial expenses (586) (370) (1,313) Financial income 281 286 591 Income before tax and investments accounted for using the equity method 2,739 4,238 7,153 (a) Joint ventures and associates with which Sanofi has entered into a strategic alliance. (b) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (c) As of June 30, 2024, this line includes a net reversal of impairment losses amounting to of €371 million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment. For 2023, this amount mainly comprises an impairment loss of €833 million, reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms. (d) This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date. (e) See note B.16. (f) See note B.17. B.20.2. OTHER SEGMENT INFORMATION The tables below show the split by operating segment of (i) the carrying amount of investments accounted for using the equity method for which Sanofi has entered into a strategic partnership agreement, (ii) acquisitions of property, plant and equipment, and (iii) acquisitions of intangible assets. Investments accounted for using the equity method in the Biopharma segment mainly comprise MSP Vaccine Company and Infraserv GmbH & Co. Höchst KG (see Note B.5.). Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period. June 30, 2024 (6 months) (€ million) Biopharma Opella Total Investments accounted for using the equity method (a) 229 14 243 Acquisitions of property, plant and equipment 882 68 950 Acquisitions of other intangible assets 922 14 936 (a) Carrying amount at the end of the reporting period. June 30, 2023 (6 months) (€ million) Biopharma Opella Total Investments accounted for using the equity method (a) 231 10 241 Acquisitions of property, plant and equipment 751 31 782 Acquisitions of other intangible assets 132 16 148 (a) Carrying amount at the end of the reporting period. December 31, 2023 (12 months) (€ million) Biopharma Opella Total Investments accounted for using the equity method (a) 234 28 262 Acquisitions of property, plant and equipment 1,619 100 1,719 Acquisitions of other intangible assets 1,287 18 1,305 (a) Carrying amount at the end of the reporting period. B.20.3. INFORMATION BY GEOGRAPHICAL REGION The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16. June 30, 2024 (6 months) (€ million) Total Europe of which France United States Other countries Net sales 21,209 4,882 1,082 9,067 7,260 Non-current assets: • property, plant and equipment 10,264 5,611 3,079 2,377 2,276 • goodwill 50,080 — — — — • other intangible assets 26,653 5,156 — 20,726 771 June 30, 2023 (6 months) (€ million) Total Europe of which France United States Other countries Net sales 20,187 5,034 1,174 7,988 7,165 Non-current assets: • property, plant and equipment 9,804 5,462 2,921 2,364 1,978 • goodwill 49,243 — — — — • other intangible assets 24,590 5,961 — 17,595 1,034 December 31, 2023 (12 months) (€ million) Total Europe of which France United States Other countries Net sales 43,070 10,392 2,379 18,512 14,166 Non-current assets: • property, plant and equipment 10,160 5,659 3,085 2,322 2,179 • goodwill 49,404 — — — — • other intangible assets 24,319 5,566 — 17,850 903 As stated in Note D.5. to the consolidated financial statements for the year ended December 31, 2023, goodwill is not allocated by geographical region.

Events Subsequent to June 30, 2

Events Subsequent to June 30, 2023	6 Months Ended
Events Subsequent to June 30, 2023	Jun. 30, 2024
Disclosure of non-adjusting events after reporting period [abstract]
Events Subsequent to June 30, 2023	C/ EVENTS SUBSEQUENT TO JUNE 30, 2024 No significant events occurred between the end of the reporting period and the date on which the condensed consolidated financial statements were signed off by the Board of Directors.

Basis of Preparation of the H_2

Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Corporate information and statement of IFRS compliance [abstract]
International Financial Reporting Standards (IFRS)	A.1. INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS) The half-year consolidated financial statements have been prepared and presented in condensed format in accordance with IAS 34 (Interim Financial Reporting). The accompanying notes therefore relate to significant events and transactions of the period, and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2023. The accounting policies used in the preparation of the consolidated financial statements as of June 30, 2024 comply with international financial reporting standards (IFRS) as endorsed by the European Union and as issued by the International Accounting Standards Board (IASB). IFRS as endorsed by the European Union as of June 30, 2024 are available via the following web link: https://www.efrag.org/Endorsement The accounting policies applied effective January 1, 2024 are identical to those presented in the consolidated financial statements for the year ended December 31, 2023. On September 22, 2022, the IASB issued an amendment to IFRS 16 (Leases) relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable from January 1, 2024 and had no impact on Sanofi's financial statements. On January 23, 2020, the IASB issued “Classification of Liabilities as Current or Non-current”, an amendment to IAS 1, and then on October 31, 2022 issued “Non-current Liabilities with Covenants”, a further amendment to IAS 1. The amendments, which are applicable from January 1, 2024, had no impact on Sanofi's financial statements. On May 25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS 7 and IFRS 7, applicable from January 1, 2024. The amendment relates to disclosures of information about such arrangements; it had no impact on the 2024 half-year financial statements . As a reminder, in its 2023 consolidated financial statements Sanofi applied “International Tax Reform – Pillar Two Model Rules”, an amendment to IAS 12 issued by the IASB on May 23, 2023, and did not recognize any deferred tax on temporary differences related to Pillar 2 rules.
Use of Estimates	A.2. USE OF ESTIMATES The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date the financial statements are finalized. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include: • amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions; • impairment of property, plant and equipment and intangible assets; • the valuation of goodwill and the valuation and useful life of acquired intangible assets; • the measurement of contingent consideration receivable in connection with asset divestments and of contingent consideration payable; • the measurement of financial assets and financial liabilities at amortized cost; • the amount of post-employment benefit obligations; • the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks; and • the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences. Actual results could differ from these estimates.
Seasonal Trends	A.3. SEASONAL TRENDS Sanofi’s activities are not subject to significant seasonal fluctuations.
Consolidation and Foreign Currency Translation of the Financial Statements of Subsidiaries in Hyperinflationary Economies	A.4. CONSOLIDATION AND FOREIGN CURRENCY TRANSLATION OF THE FINANCIAL STATEMENTS OF SUBSIDIARIES IN HYPERINFLATIONARY ECONOMIES In 2024, Sanofi continues to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met.The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial. In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July 1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level. In Turkey, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January 1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level.
Fair Value of Financial Instruments	A.5. FAIR VALUE OF FINANCIAL INSTRUMENTS Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels: • Level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging); • Level 2: quoted prices in active markets for similar assets or liabilities, or valuation techniques in which all important inputs are derived from observable market data; and • Level 3: valuation techniques in which not all important inputs are derived from observable market data. The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments. Note Type of financial instrument Measurement principle Level in fair value hierarchy Valuation technique Method used to determine fair value Market data Valuation model Exchange rate Interest rate Volatilities B.6. Financial assets measured at fair value (quoted equity instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (quoted debt instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (unquoted equity instruments) Fair value 3 Amortized cost/ Peer comparison (primarily) If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used. B.6. Financial assets at fair value (contingent consideration receivable) Fair value 3 Revenue-based approach The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2021. B.6. Long-term loans and advances and other non-current receivables Amortized cost N/A N/A The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value. B.6. Financial assets measured at fair value held to meet obligations under post-employment benefit plans Fair value 1 Market value Quoted market price N/A B.6. Financial assets designated at fair value held to meet obligations under deferred compensation plans Fair value 1 Market value Quoted market price N/A B.9. Investments in mutual funds Fair value 1 Market value Net asset value N/A B.9. Negotiable debt instruments, commercial paper, instant access deposits and term deposits Amortized cost N/A N/A Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements. B.9. Financial Debt Amortized cost (a) N/A N/A In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments). For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections. B.9. Lease liabilities Amortized cost N/A N/A Future lease payments are discounted using the incremental borrowing rate. B.10. Forward currency contracts Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market N/A B.10. Interest rate swaps Fair value 2 Revenue-based approach Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and Euronext interest rate futures > 1 year: Mid Zero Coupon N/A B.10. Cross-currency swaps Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and Euronext interest rate futures > 1 year: Mid Zero Coupon N/A B.11. Liabilities related to business combinations and to non-controlling interests Fair value 3 Revenue-based approach Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11. (a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).
New Pronouncements Issued by the IASB and Applicable from 2024	A.6. NEW PRONOUNCEMENTS ISSUED BY THE IASB AND APPLICABLE FROM 2025 On August 15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS 21 (The Effects of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable from January 1, 2025 (subject to endorsement by the European Union); it will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it . On April 9, 2024, the IASB issued IFRS 18 (Presentation and Disclosure in Financial Statements), applicable from January 1, 2027 (subject to endorsement by the European Union). An impact assessment is currently under way. Sanofi will not early adopt this new standard. On May 30, 2024, the IASB issued amendments to IFRS 9 and IFRS 7 relating to the classification and measurement of financial instruments, applicable no earlier than January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact, and will not early adopt these amendments. On July 18, 2024, the IASB issued Volume 11 of “Annual Improvements to IFRS”, applicable from January 1, 2026 (subject to endorsement by the European Union). Sanofi does not expect any material impact from those improvements to various standards, which are essentially in the nature of clarifications, and will not early adopt them.
Agreements Relating to the Recombinant COVID-19 Vaccine Candidate Developed by Sanofi in Collaboration with GSK

Basis of Preparation of the H_3

Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2024
Corporate information and statement of IFRS compliance [abstract]
Disclosure of Measurement Principles Applied to Financial Instruments	The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments. Note Type of financial instrument Measurement principle Level in fair value hierarchy Valuation technique Method used to determine fair value Market data Valuation model Exchange rate Interest rate Volatilities B.6. Financial assets measured at fair value (quoted equity instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (quoted debt instruments) Fair value 1 Market value Quoted market price N/A B.6. Financial assets measured at fair value (unquoted equity instruments) Fair value 3 Amortized cost/ Peer comparison (primarily) If cost ceases to be a representative measure of fair value, an internal valuation based primarily on peer comparison is used. B.6. Financial assets at fair value (contingent consideration receivable) Fair value 3 Revenue-based approach The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3. to the consolidated financial statements for the year ended December 31, 2021. B.6. Long-term loans and advances and other non-current receivables Amortized cost N/A N/A The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value. B.6. Financial assets measured at fair value held to meet obligations under post-employment benefit plans Fair value 1 Market value Quoted market price N/A B.6. Financial assets designated at fair value held to meet obligations under deferred compensation plans Fair value 1 Market value Quoted market price N/A B.9. Investments in mutual funds Fair value 1 Market value Net asset value N/A B.9. Negotiable debt instruments, commercial paper, instant access deposits and term deposits Amortized cost N/A N/A Because these instruments have a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements. B.9. Financial Debt Amortized cost (a) N/A N/A In the case of financial liabilities with a maturity of less than 3 months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. For financial liabilities with a maturity of more than 3 months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments). For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections. B.9. Lease liabilities Amortized cost N/A N/A Future lease payments are discounted using the incremental borrowing rate. B.10. Forward currency contracts Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market N/A B.10. Interest rate swaps Fair value 2 Revenue-based approach Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and Euronext interest rate futures > 1 year: Mid Zero Coupon N/A B.10. Cross-currency swaps Fair value 2 Present value of future cash flows Mid Market Spot < 1 year: Mid Money Market and Euronext interest rate futures > 1 year: Mid Zero Coupon N/A B.11. Liabilities related to business combinations and to non-controlling interests Fair value 3 Revenue-based approach Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.11. (a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
Property, Plant and Equipment (Tables)	Jun. 30, 2024
Property, plant and equipment [abstract]
Summary of Acquisitions and Capitalized Interest by Operating Segment	The table below sets forth acquisitions and capitalized interest by operating segment for the first half of 2024: (€ million) June 30, 2024 December 31, 2023 Acquisitions 591 1,693 Biopharma 535 1,592 Of which Manufacturing & Supply 366 1,188 Opella 56 101 Of which Manufacturing & Supply 41 90 Of which capitalized interest 22 26

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
Goodwill and Other Intangible Assets (Tables)	Jun. 30, 2024
Intangible assets and goodwill [abstract]
Schedule of Movements in Other Intangible Assets	Movements in other intangible assets during the first half of 2024 were as follows: (€ million) Acquired R&D Products, trademarks and other rights Software Total other intangible assets Gross value at January 1, 2024 9,772 73,733 1,808 85,313 Changes in scope of consolidation (a) 1,766 — — 1,766 Acquisitions and other increases 571 201 41 813 Disposals and other decreases (49) (27) (7) (83) Currency translation differences 236 1,050 7 1,293 Transfers 2 12 (1) 13 Gross value at June 30, 2024 12,298 74,969 1,848 89,115 Accumulated amortization and impairment at January 1, 2024 (a) (3,734) (55,908) (1,352) (60,994) Amortization expense — (1,084) (52) (1,136) Impairment losses, net of reversals (b) (13) 379 — 366 Disposals and other decreases 49 27 6 82 Currency translation differences (70) (701) (4) (775) Transfers — (4) (1) (5) Accumulated amortization and impairment at June 30, 2024 (3,768) (57,291) (1,403) (62,462) Carrying amount at January 1, 2024 6,038 17,825 456 24,319 Carrying amount at June 30, 2024 8,530 17,678 445 26,653 (a) Impact of the acquisition of Inhibrx, Inc (see Note B.1.). (b)

Investments Accounted for Usi_2

Investments Accounted for Using the Equity Method (Tables)	6 Months Ended
Investments Accounted for Using the Equity Method (Tables)	Jun. 30, 2024
Interests In Other Entities [Abstract]
Summary of Investments in Associates and Joint Ventures	Investments accounted for using the equity method consist of associates and joint ventures (see Note B.1. to the consolidated financial statements for the year ended December 31, 2023), and comprise: (€ million) % interest June 30, 2024 December 31, 2023 EUROAPI (a) 29.8 72 162 Infraserv GmbH & Co. Höchst KG (b) 31.2 89 90 MSP Vaccine Company (c) 50.0 90 96 Other investments — 64 76 Total 315 424 (a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€2.55 as of June 30, 2024, and €5.73 as of December 31, 2023). (b) Joint venture. (c) Joint venture MSP Vaccine Company owns 100% of MCM Vaccine BV.
Summary of Principal Transactions and Balances with Related Parties	The financial statements include commercial transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below: (€ million) June 30, 2024 June 30, 2023 December 31, 2023 Sales 59 64 157 Royalties and other income 61 32 63 Accounts receivable and other receivables 278 213 249 Purchases of goods and services 345 302 642 Accounts payable and other payables 63 97 71

Other Non-Current Assets (Table

Other Non-Current Assets (Tables)	6 Months Ended
Other Non-Current Assets (Tables)	Jun. 30, 2024
Subclassifications of assets, liabilities and equities [abstract]
Summary of Other Non-Current Assets	Other non-current assets comprise: (€ million) June 30, 2024 December 31, 2023 Equity instruments at fair value through other comprehensive income 1,161 1,088 Debt instruments at fair value through other comprehensive income 347 346 Other financial assets at fair value through profit or loss 817 808 Pre-funded pension obligations 325 271 Long-term prepaid expenses 95 114 Long-term loans and advances and other non-current receivables 587 591 Total 3,333 3,218

Accounts Receivable (Tables)

Accounts Receivable (Tables)	6 Months Ended
Accounts Receivable (Tables)	Jun. 30, 2024
Trade and other receivables [abstract]
Summary of Accounts Receivable	Accounts receivable break down as follows: (€ million) June 30, 2024 December 31, 2023 Gross value 8,602 8,528 Allowances (92) (95) Carrying amount 8,510 8,433
Summary of Gross Value of Overdue Receivables	The table below shows the ageing profile of overdue accounts receivable, based on gross value: (€ million) Overdue accounts gross value Overdue by <1 month Overdue by 1-3 months Overdue by 3-6 months Overdue by 6-12 months Overdue by > 12 months June 30, 2024 646 264 105 137 69 71 December 31, 2023 689 269 154 123 62 81

Consolidated Shareholders' Eq_2

Consolidated Shareholders' Equity (Tables)	6 Months Ended
Consolidated Shareholders' Equity (Tables)	Jun. 30, 2024
Share Capital, Reserves And Other Equity Interest [Abstract]
Summary of Treasury Shares Held	B.8. CONSOLIDATED SHAREHOLDERS’ EQUITY B.8.1. SHARE CAPITAL As of June 30, 2024, the share capital was €2,532,725,512 and consisted of 1,266,362,756 shares (the total number of shares outstanding) with a par value of €2. Treasury shares held by Sanofi are as follows: Number of shares % of share capital June 30, 2024 15.33 1.211 % December 31, 2023 13.45 1.063 % June 30, 2023 10.90 0.864 % January 1, 2023 8.20 0.650 % A total of 91,355 shares were issued in the first half of 2024 as a result of the exercise of Sanofi stock subscription options. In addition, 2,803,637 shares vested under Sanofi restricted share plans during the first half of 2024, of which 1,471,432 were fulfilled by issuance of new shares and 1,332,205 by allotment of existing shares free of charge .
Summary of Principal Characteristics of Restricted Share Plans	Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. to the consolidated financial statements for the year ended December 31, 2023. The principal features of the plans awarded in 2024 are set forth below: 2024 Type of plan Performance share plan Date of Board meeting approving the plan April 30, 2024 Total number of shares subject to a 3-year service period 4,505,145 Of which with no market condition 2,888,502 Fair value per share awarded (a) €81.84 Of which with market conditions 1,616,643 Fair value per share awarded other than to the Chief Executive Officer (1,394,478 shares in total) (b) €72.79 Fair value per share awarded other than to the Chief Executive Officer (139,665 additional shares) (c) €13.50 Fair value per share awarded to the Chief Executive Officer (82,500 shares) (b) €72.38 Fair value of plan at the date of grant (€ million) 346 (a) Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period. (b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period. (c) Additional tranche subject to a higher level of market conditions.
Summary of Number of Restricted Shares Not Yet Fully Vested	The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below: June 30, 2024 June 30, 2023 Total expense for restricted share plans (€ million) 128 108 Number of shares not yet fully vested 11,192,984 10,127,545 Under 2024 plans 4,498,109 — Under 2023 plans 3,652,352 3,837,974 Under 2022 plans 3,031,060 3,226,321 Under 2021 plans 11,463 2,996,101 Under 2020 plans — 67,149
Summary of Options Outstanding and Exercisable	The table below provides summary information about options outstanding and exercisable as of June 30, 2024: Range of exercise prices per share Outstanding Exercisable Number of options Weighted average residual life (years) Weighted average exercise price per share (€) Number of options Weighted average exercise price per share (€) From €60.00 to €70.00 per share 168,784 3.84 65.84 168,784 65.84 From €70.00 to €80.00 per share 478,150 3.18 76.26 478,150 76.26 From €80.00 to €90.00 per share 594,724 1.79 89.20 594,724 89.20 Total 1,241,658 1,241,658
Summary of Number of Shares Used to Compute Diluted Earnings Per Share	Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares. (million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Average number of shares outstanding 1,249.4 1,249.9 1,251.7 Adjustment for stock options with dilutive effect 0.1 0.3 0.2 Adjustment for restricted shares 4.3 4.3 4.5 Average number of shares used to compute diluted earnings per share 1,253.8 1,254.5 1,256.4
Summary of Movements within Other Comprehensive Income	Movements within other comprehensive income are shown below: (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Actuarial gains/(losses): ▪ Actuarial gains/(losses) excluding investments accounted for using the equity method 235 133 (171) ▪ Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes — 8 — ▪ Tax effects (57) (60) 18 Equity instruments included in financial assets and financial liabilities: — — — ▪ Change in fair value (excluding investments accounted for using the equity method) (10) 3 97 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — — — ▪ Equity risk hedging instruments designated as fair value hedges — — — ▪ Tax effects (2) 1 (21) Items not subsequently reclassifiable to profit or loss 166 85 (77) Debt instruments included in financial assets: ▪ Change in fair value (excluding investments accounted for using the equity method) (a) (5) 6 21 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) — — — ▪ Tax effects 1 (1) (4) Cash flow hedges and fair value hedges: ▪ Change in fair value (excluding investments accounted for using the equity method) (b) (4) 1 1 ▪ Change in fair value (investments accounted for using the equity method, net of taxes) 1 — (2) ▪ Tax effects 1 — — Change in currency translation differences: ▪ Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method) (c) 1,167 (1,089) (1,551) ▪ Currency translation differences (investments accounted for using the equity method) (1) 6 3 ▪ Hedges of net investments in foreign operations (126) 26 8 ▪ Tax effects 33 (7) (2) Items subsequently reclassifiable to profit or loss 1,067 (1,058) (1,526) (a) Includes reclassifications to profit or loss: immaterial over all periods. (b) Includes reclassifications to profit or loss: immaterial over all periods. (c) Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar. Includes a reclassification to profit or loss: immaterial in the first half of 2024 , €(56) million in 2023 and €(14) million in the first half of 2023.

Debt, Cash and Cash Equivalen_2

Debt, Cash and Cash Equivalents (Tables)	6 Months Ended
Debt, Cash and Cash Equivalents (Tables)	Jun. 30, 2024
Cash and cash equivalents [abstract]
Summary of Changes in Financial Position	Changes in financial position during the period were as follows: (€ million) June 30, 2024 December 31, 2023 Long-term debt 12,503 14,347 Short-term debt and current portion of long-term debt 9,236 2,045 Interest rate and currency derivatives used to manage debt 179 139 Total debt 21,918 16,531 Cash and cash equivalents (6,795) (8,710) Interest rate and currency derivatives used to manage cash and cash equivalents (11) (28) Net debt (a) 15,112 7,793 (a) Net debt does not include lease liabilities, which amounted to €2,012 million as of June 30, 2024 and €2,030 million as of December 31, 2023.
Summary of Reconciliation of Carrying Amount to Value on Redemption	A reconciliation of the carrying amount of net debt in the balance sheet to value on redemption as of June 30, 2024 is shown below: (€ million) Value on redemption Carrying amount at June 30, 2024 Amortized cost Adjustment to debt measured at fair value June 30, 2024 December 31, 2023 Long-term debt 12,503 35 150 12,688 14,546 Short-term debt and current portion of long-term debt 9,236 — 18 9,254 2,045 Interest rate and currency derivatives used to manage debt 179 — (169) 10 (18) Total debt 21,918 35 (1) 21,952 16,573 Cash and cash equivalents (6,795) — — (6,795) (8,710) Interest rate and currency derivatives used to manage cash and cash equivalents (11) — — (11) (28) Net debt (a) 15,112 35 (1) 15,146 7,835 (a) Net debt does not include lease liabilities, which amounted to €2,012 million as of June 30, 2024 and €2,030 million as of December 31, 2023.
Summary of Net Debt by Type Valuation of Redemption	The table below shows an analysis of net debt by type, at value on redemption: (€ million) June 30, 2024 December 31, 2023 non-current current Total non-current current Total Bond issues 12,593 1,916 14,509 14,416 718 15,134 Other bank borrowings 95 7,118 (a) 7,213 130 1,118 1,248 Other borrowings — 5 5 — 6 6 Bank credit balances — 215 215 — 203 203 Interest rate and currency derivatives used to manage debt — 10 10 — (18) (18) Total debt 12,688 9,264 21,952 14,546 2,027 16,573 Cash and cash equivalents — (6,795) (6,795) — (8,710) (8,710) Interest rate and currency derivatives used to manage cash and cash equivalents — (11) (11) — (28) (28) Net debt 12,688 2,458 15,146 14,546 (6,711) 7,835 (a) As of June 30, 2024, current other bank borrowings includ e €6,955 million related to the US Commercial Paper program and €0 million related to the Negotiable European Commercial Paper program in France.
Summary of Market Value of Net Debt	The market value of Sanofi’s debt, net of cash and cash equivalents and derivatives and excluding accrued interest, is as follows: (€ million) June 30, 2024 December 31, 2023 Market value 14,214 7,086 Value on redemption 15,146 7,835

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	6 Months Ended
Derivative Financial Instruments (Tables)	Jun. 30, 2024
Financial Instruments [Abstract]
Summary of Operating Currency Hedging Instruments	The table below shows operating currency hedging instruments in place as of June 30, 2024. The notional amount is translated into euros at the relevant closing exchange rate. June 30, 2024 Of which derivatives designated as cash flow hedges Of which derivatives not eligible for hedge accounting (€ million) Notional amount Fair value Notional amount Fair value Of which recognized in equity Notional amount Fair value Forward currency sales 5,120 (45) — — — 5,120 (45) of which US dollar 2,152 (17) — — — 2,152 (17) of which Chinese yuan renminbi 608 — — — — 608 — of which Russian rouble 252 (31) — — — 252 (31) of which Japanese yen 269 5 — — — 269 5 of which Singapore dollar 197 (1) — — — 197 (1) Forward currency purchases 3,195 21 — — — 3,195 21 of which US dollar 1,733 2 — — — 1,733 2 of which Singapore dollar 398 1 — — — 398 1 of which Russian rouble 203 12 — — — 203 12 of which Turkish lira 108 7 — — — 108 7 of which Canadian dollar 100 1 — — — 100 1 Total 8,315 (24) — — — 8,315 (24) The above positions mainly hedge material foreign currency cash flows arising after the end of the reporting period in relation to transactions carried out during the six months ended June 30, 2024 and recognized in the balance sheet at that date. Gains and losses on hedging in struments (forward contracts) are calculated and recognized in parallel with the recognition of gains and losses on the hedged items. Due to this hedging relationship, the commercial foreign exchange difference on those items (hedging instruments and hedged transactions) will be immaterial in the second half of 2024 .
Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated	The table below shows financial currency hedging instruments in place as of June 30, 2024. The notional amount is translated into euros at the relevant closing exchange rate. June 30, 2024 (€ million) Notional amount Fair value Maximum expiry date Forward currency sales 7,190 (30) of which US dollar 5,797 (a) (28) 2024 of which Chinese yuan renminbi 301 (1) 2024 of which Canadian dollar 190 (1) 2024 Forward currency purchases 7,656 42 of which US dollar 5,242 (b) (c) 37 2025 of which Singapore dollar 1,768 7 2024 of which Hungarian forint 182 (1) 2024 Total 14,846 12 (a) Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi’s net investment in Bioverativ. As of June 30, 2024, the fair value of these forward contracts represented a liability of €26 million; the opposite entry was recognized in “Other comprehensive income”, with the impact on financial income and expense being immaterial. (b) Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of June 30, 2024, the fair value of these contracts represented an asset of €2 million, with €0 million credited to “Other comprehensive income” to recognize the hedging cost. (c) Includes forward purchases with a notional amount of $1,080 million expiring in 2024 , designated as a fair value hedge of $1,080 million of commercial paper. As of June 30, 2024, the fair value of these contracts represented an asset of €16 million, with €0 million credited to “Other comprehensive income” to recognize the hedging cost. .
Disclosure of Instruments	The table below shows instruments of this type in place as of June 30, 2024: Of which designated as fair value hedges Of which designated as cash flow hedges (€ million) 2024 2025 2026 2027 2028 and beyond Total Fair value Notional amount Fair value Notional amount Fair value Of which recognized in equity Interest rate swaps pay capitalized SOFR USD / receive 1.02% — — — — 467 467 (53) 467 (53) — — — pay capitalized SOFR USD / receive 1.32% — — — — 467 467 (48) 467 (48) — — — pay capitalized Ester / receive 0.69% — 850 — — — 850 (24) 850 (24) — — — pay capitalized Ester / receive 0.92% — — — — 650 650 (56) 650 (56) — — — pay capitalized Ester / receive 3.56% 997 — — — — 997 — 997 — — — — Total 997 850 — — 1,584 3,431 (181) 3,431 (181) — — —

Liabilities Related to Business

Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure of contingent liabilities in business combination [abstract]
Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests	Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2024 are shown below: (€ million) MSD contingent consideration (European Vaccines business) Shire contingent consideration arising from acquisition of Translate Bio Contingent consideration arising from acquisition of Amunix Other Total (a) Balance at January 1, 2024 127 441 137 4 709 Payments made (71) — — — (71) Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (b) 4 71 — — 75 Other movements — — — (3) (3) Currency translation differences 1 14 3 — 18 Balance at June 30, 2024 61 526 140 1 728 Of which: • Current portion 201 • Non-current portion 527 (a) As of January 1, 2024, this comprised a non-current portion of €501 million and a current portion of €208 million. (b) Amounts mainly reported within the income statement line item “Fair value remeasurement of contingent consideration”.

Non-Current Provisions And Ot_2

Non-Current Provisions And Other Non-Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Subclassifications of assets, liabilities and equities [abstract]
Summary of Non-Current Provisions and Other Non-Current Liabilities	The line item Non-current provisions and other non-current liabilities comprises the following: (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Provisions 5,918 5,018 5,262 Other non-current liabilities (a) 2,301 2,070 2,340 Total 8,219 7,088 7,602 (a) Includes €1,970 million at June 30, 2024 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States. Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is €1,147 million; the nominal value of payments estimated to be due after more than five years is €2,679 million.
Summary of Movements in Non-Current Provisions	The table below shows movements in provisions: (€ million) Provisions for pensions & other post-employment benefits Provisions for other long-term benefits Restructuring provisions Other provisions Total Balance at January 1, 2024 2,214 718 554 1,776 5,262 Increases in provisions and other liabilities 72 (a) 89 581 559 1,301 Provisions utilized (78) (a) (65) (11) (76) (230) Reversals of unutilized provisions (63) (a) 1 (4) (53) (119) Transfers (b) 75 — (173) (24) (122) Net interest related to employee benefits, and unwinding of discount 37 3 9 11 60 Currency translation differences 18 13 (47) 17 1 Actuarial gains and losses on defined-benefit plans (B.12.1.) (235) — — — (235) Balance at June 30, 2024 2,040 759 909 2,210 5,918 (a) In the case of “Provisions for pensions and other post-employment benefits”, the “Increases in provisions” line corresponds to rights vesting in employees during the period, and past service cost; the “Provisions utilized” line corresponds to contributions paid into pension funds and to beneficiaries; and the “Reversals of unutilized provisions” line corresponds to plan curtailments, settlements and amendments. (b) Mainly transfers to the line “Current provisions and other current liabilities”.
Disclosure of Remeasurement of Net Defined Benefit Liability Asset	Actuarial gains and losses arising on pensions and other post-employment benefits and recognized in equity are as follows (amounts reported before tax): (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Actuarial gains/(losses) on plan assets (138) 34 (208) Actuarial gains/(losses) on benefit obligations 373 (a) 99 (b) 379 (a) Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the change in the inflation rate in the United Kingdom (+0.10%) in the first half of 2024. (b) Includes the effects of (i) the change in discount rates (in a range between -0.15% and +0.40%) and (ii) the change in the inflation rate in the eurozone (-0.10%) in the first half of 2023.

Other Operating Income And Ex_2

Other Operating Income And Expenses (Tables)	6 Months Ended
Other Operating Income And Expenses (Tables)	Jun. 30, 2024
Analysis of income and expense [abstract]
Schedule of Other Operating Expenses	Other operating expenses for the first half of 2024 included €1,841 million of expenses related to Regeneron (compared with €1,423 million in the first half of 2023), as shown in the table below. (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance (1,934) (1,449) (3,321) Additional share of profit paid by Regeneron towards development costs 389 291 668 Reimbursement to Regeneron of selling expenses incurred (292) (260) (543) Total: Monoclonal Antibody Alliance (1,837) (1,418) (3,196) Other (mainly Zaltrap and Libtayo) 92 97 217 Other operating income/(expenses), net related to Regeneron (1,745) (1,321) (2,979) of which amount presented in “Other operating income” 96 102 227

Restructuring Costs and Simil_2

Restructuring Costs and Similar Items (Tables)	6 Months Ended
Restructuring Costs and Similar Items (Tables)	Jun. 30, 2024
Analysis of income and expense [abstract]
Summary of Restructuring Costs and Similar Items	Restructuring costs and similar items comprise the following: (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Employee-related expenses 849 185 489 Charges, gains or losses on assets (a) (31) 86 293 Costs of transformation programs 347 265 676 Other restructuring costs 166 11 32 Total 1,331 547 1,490 (a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.

Financial Expenses and Income (

Financial Expenses and Income (Tables)	6 Months Ended
Financial Expenses and Income (Tables)	Jun. 30, 2024
Analysis of income and expense [abstract]
Summary of Analysis of Financial Income and Expenses	An analysis of financial expenses and income is set forth below: (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Cost of debt (a) (309) (232) (555) Interest income (b) 243 257 533 Cost of net debt (66) 25 (22) Non-operating foreign exchange gains/(losses) 1 (3) (2) Unwinding of discounting of provisions (c) (17) (22) (59) Net interest cost related to employee benefits (40) (41) (73) Gains/(losses) on disposals of financial assets — — (1) Net interest expense on lease liabilities (22) (21) (39) Other (d) (161) (22) (526) Net financial income/(expenses) (305) (84) (722) comprising: Financial expenses (586) (370) (1,313) Financial income 281 286 591 (a) Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: €(24) million in the first half of 2024, €(25) million in the first half of 2023, and €(67) million over the whole of 2023. (b) Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: €(18) million in the first half of 2024, €(4) million in the first half of 2023, and €(13) million over the whole of 2023. (c) Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.). (d) Includes a financial expense of €176 million for the six months ended June 30, 2024 (€541 million for the year ended December 31, 2023, €35 million for the six months ended June 30, 2023) for the remeasurement of the liability recorded in the balance sheet for estimated future royalties on Beyfortus sales in the US.

Income Tax Expense (Tables)

Income Tax Expense (Tables)	6 Months Ended
Income Tax Expense (Tables)	Jun. 30, 2024
Income taxes paid (refund) [abstract]
Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes	The table below shows the allocation of income tax expense between current and deferred taxes: (€ million) June 30, 2024 (6 months) June 30, 2023 (6 months) December 31, 2023 (12 months) Current taxes (1,243) (1,171) (2,560) Deferred taxes 780 441 958 Total (463) (730) (1,602) Income before tax and investments accounted for using the equity method 2,739 4,238 7,153
Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate	The difference between the effective tax rate (on income before tax and investments accounted for using the equity method) and the standard corporate income tax rate applicable in France is explained as follows: (as a percentage) June 30, 2024 (6 months) (a) June 30, 2023 (6 months) (a) December 31, 2023 (12 months) Standard tax rate applicable in France 25.8 25.8 25.8 Difference between the standard French tax rate and the rates applicable to Sanofi (b) (14.3) (8.2) (13.6) Probable reversal of temporary differences on investments in Opella subsidiaries (c) — — 5.1 Revisions to tax exposures and settlements of tax disputes 3.2 0.5 2.7 Fair value remeasurement of contingent consideration liabilities — — 0.1 Other (d) 2.2 (0.8) 2.3 Effective tax rate 16.9 17.3 22.4 (a) Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.). (b) The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France. (c) In accordance with IAS12, a deferred tax liability was recognised in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Opella business, as announced in October 2023. (d) For the six months ended June 30, 2024, this line includes a tax expense of €52 million, representing the estimated impact of Pillar 2 based on Sanofi’s current understanding of Pillar Two rules.

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
Segment Information (Tables)	Jun. 30, 2024
Disclosure of operating segments [abstract]
Summary of Net Sales by Segment and Geographical Area	The table below sets forth net sales for the six months ended June 30, 2024 and June 30, 2023: (€ million) Europe United States Other June 30, 2024 Europe United Other June 30, 2023 Total Biopharma 4,074 8,294 6,010 18,378 4,194 7,366 5,907 17,467 Total Pharma 3,692 7,550 4,817 16,059 3,624 6,709 4,744 15,077 Dupixent 770 4,437 931 6,138 587 3,682 609 4,878 Total Pharma launches 249 868 178 1,295 168 460 87 715 of which Nexviazyme 95 174 51 320 42 123 19 184 Sarclisa 64 100 63 227 56 76 49 181 ALTUVIIIO — 259 21 280 — 17 2 19 Rezurock 12 188 7 207 2 140 (1) 141 Cablivi 43 60 10 113 49 58 6 113 Xenpozyme 24 37 11 72 15 21 2 38 Enjaymo 10 30 15 55 4 19 10 33 Tzield 1 20 — 21 — 6 — 6 Total other products 2,673 2,245 3,708 8,626 2,869 2,567 4,048 9,484 of which Industrial sales 274 3 1 278 264 3 13 280 Total Vaccines 382 744 1,193 2,319 570 657 1,163 2,390 of which Influenza Vaccines 30 16 142 188 37 19 106 162 Polio/Pertussis/ 248 311 789 1,348 231 347 850 1,428 RSV vaccines (Beyfortus) 7 116 77 200 — — — — Meningitis, travel and endemics vaccines 97 301 184 582 72 291 206 569 Total Opella 808 773 1,250 2,831 840 622 1,258 2,720 of which Seasonal symptoms & pain relief 1,216 1,261 Wellness brands 1,258 1,112 Others 357 347 Total net sales 4,882 9,067 7,260 21,209 5,034 7,988 7,165 20,187
Schedule of Segment Results	Segment results are shown in the table below: June 30, 2024 (6 months) (€ million) Biopharma Opella Other (a) Total Net sales 18,378 2,831 — 21,209 Other revenues 1,257 32 — 1,289 Cost of sales (5,756) (1,077) 3 (6,830) Research and development expenses (3,331) (92) — (3,423) Selling and general expenses (4,260) (1,002) 2 (5,260) Other operating income and expenses (1,417) 43 (19) (1,393) Share of profit/(loss) from investments accounted for using the equity method 66 9 — 75 Net income attributable to non-controlling interests (6) (5) — (11) Business operating income 4,931 739 (14) 5,656 (a) The “Other” column reconciles segmental results to the total per the consolidated financial statements. . June 30, 2023 (6 months) (€ million) Biopharma Opella Other (a) Total Net sales 17,467 2,720 — 20,187 Other revenues 1,331 27 — 1,358 Cost of sales (5,388) (949) (5) (6,342) Research and development expenses (3,082) (111) — (3,193) Selling and general expenses (4,248) (936) 2 (5,182) Other operating income and expenses (897) 100 (8) (805) Share of profit/(loss) from investments accounted for using the equity method 48 7 — 55 Net income attributable to non-controlling interests (11) (8) — (19) Business operating income 5,220 850 (11) 6,059 (a) The “Other” column reconciles segmental results to the total per the consolidated financial statements. December 31, 2023 (12 months) (€ million) Biopharma Opella Other (a) Total Net sales 37,890 5,180 — 43,070 Other revenues 3,322 52 — 3,374 Cost of sales (12,282) (1,933) (1) (14,216) Research and development expenses (6,509) (219) — (6,728) Selling and general expenses (8,868) (1,828) 4 (10,692) Other operating income and expenses (2,387) 181 (18) (2,224) Share of profit/(loss) from investments accounted for using the equity method 101 21 — 122 Net income attributable to non-controlling interests (20) (16) — (36) Business operating income 11,247 1,438 (15) 12,670 (a) The “Other” column reconciles segmental results to the total per the consolidated financial statements.
Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method	The table below, presented in compliance with IFRS 8, shows a reconciliation between “Business operating income” and Income before tax and investments accounted for using the equity method : (€ million) June 30, 2024 ( 6 months) June 30, 2023 ( 6 months) December 31, 2023 (12 months) Business operating income 5,656 6,059 12,670 Share of profit/(loss) from investments accounted for using the equity method (a) (75) (55) (122) Net income attributable to non-controlling interests (b) 11 19 36 Amortization and impairment of intangible assets (c) (690) (1,050) (3,068) Fair value remeasurement of contingent consideration (66) (26) (93) Expense arising from the impact of acquisitions on inventories (d) (19) (5) (20) Restructuring costs and similar items (e) (1,331) (547) (1,490) Other gains and losses, and litigation (f) (442) (73) (38) Operating income 3,044 4,322 7,875 Financial expenses (586) (370) (1,313) Financial income 281 286 591 Income before tax and investments accounted for using the equity method 2,739 4,238 7,153 (a) Joint ventures and associates with which Sanofi has entered into a strategic alliance. (b) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (c) As of June 30, 2024, this line includes a net reversal of impairment losses amounting to of €371 million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment. For 2023, this amount mainly comprises an impairment loss of €833 million, reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms. (d) This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date. (e) See note B.16. (f) See note B.17.
Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment	Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period. June 30, 2024 (6 months) (€ million) Biopharma Opella Total Investments accounted for using the equity method (a) 229 14 243 Acquisitions of property, plant and equipment 882 68 950 Acquisitions of other intangible assets 922 14 936 (a) Carrying amount at the end of the reporting period. June 30, 2023 (6 months) (€ million) Biopharma Opella Total Investments accounted for using the equity method (a) 231 10 241 Acquisitions of property, plant and equipment 751 31 782 Acquisitions of other intangible assets 132 16 148 (a) Carrying amount at the end of the reporting period. December 31, 2023 (12 months) (€ million) Biopharma Opella Total Investments accounted for using the equity method (a) 234 28 262 Acquisitions of property, plant and equipment 1,619 100 1,719 Acquisitions of other intangible assets 1,287 18 1,305
Summary of Geographical Information on Net Sales and Non-Current Assets	In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16. June 30, 2024 (6 months) (€ million) Total Europe of which France United States Other countries Net sales 21,209 4,882 1,082 9,067 7,260 Non-current assets: • property, plant and equipment 10,264 5,611 3,079 2,377 2,276 • goodwill 50,080 — — — — • other intangible assets 26,653 5,156 — 20,726 771 June 30, 2023 (6 months) (€ million) Total Europe of which France United States Other countries Net sales 20,187 5,034 1,174 7,988 7,165 Non-current assets: • property, plant and equipment 9,804 5,462 2,921 2,364 1,978 • goodwill 49,243 — — — — • other intangible assets 24,590 5,961 — 17,595 1,034 December 31, 2023 (12 months) (€ million) Total Europe of which France United States Other countries Net sales 43,070 10,392 2,379 18,512 14,166 Non-current assets: • property, plant and equipment 10,160 5,659 3,085 2,322 2,179 • goodwill 49,404 — — — — • other intangible assets 24,319 5,566 — 17,850 903

Basis of Preparation of the H_4

Basis of Preparation of the Half-Year Financial Statements and Accounting Policies (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disclosure of initial application of standards or interpretations [line items]
Other revenues	€ 1,289	€ 1,358	€ 3,374
Argentina
Disclosure of initial application of standards or interpretations [line items]
Cumulative consumer price inflation rate	100%
Turkey
Disclosure of initial application of standards or interpretations [line items]
Cumulative consumer price inflation rate	100%

Principal Changes in Scope of_2

Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details) $ / shares in Units, € in Millions, $ in Millions		6 Months Ended			12 Months Ended
		Jun. 30, 2024 EUR (€)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 EUR (€)	Dec. 31, 2023 EUR (€)	May 30, 2024 EUR (€)	May 30, 2024 USD ($) $ / shares
Disclosure of detailed information about business combination [line items]
Net cash flow on acquisition \| €	[1]	€ 1,885		€ 2,465	€ 3,870
Name of acquiree		Inhibrx, Inc	Inhibrx, Inc
Assets Acquisition
Disclosure of detailed information about business combination [line items]
Consideration transferred, acquisition-date fair value							$ 2,035
Identifiable intangible assets recognised as of acquisition date							$ 1,908
Net cash flow on acquisition			$ 2,035
Assets Acquisition Nominal Value \| €						€ 300
Assets Acquisition, Purchase Price Per Share \| $ / shares							$ 5

[1] For the six months ended June 30, 2024, this line item includes the net cash outflow arising from the acquisition of Inhibrx, Inc. (see Note B.1.1.). For the six months ended June 30, 2023, this line includes the net cash outflow arising from the acquisition of Provention Bio Inc. For the year ended December 31, 2023, it includes the net cash outflow arising from the acquisitions of Provention Bio Inc and QRIB.

Principal Changes in Scope of_3

Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Amendments to Principal Agreements (Details) - EUR (€) € in Millions		6 Months Ended
		Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Disclosure Of Principal Agreements [Line Items]
Other non-current liabilities	[1]	€ 2,301	€ 2,340	€ 2,070
Other intangible assets excluding software
Disclosure Of Principal Agreements [Line Items]
Acquisitions and other increases		772
Antibodies Collaboration Agreement \| Swedish Orphan Biovitrum AB
Disclosure Of Principal Agreements [Line Items]
Other non-current liabilities		€ 1,970

[1]a) Includes €1,970 million at June 30, 2024 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States. Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is €1,147 million; the nominal value of payments estimated to be due after more than five years is €2,679 million

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Acquisitions and Capitalized Interest by Operating Segment (Details) € in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2024 EUR (€) segment	Dec. 31, 2023 EUR (€)
Disclosure of detailed information about property, plant and equipment [line items]
Additions other than through business combinations, property, plant and equipment	€ 591	€ 1,693
Interest costs capitalised	€ 22	26
Number of operating segments \| segment	2
Dupixent
Disclosure of detailed information about property, plant and equipment [line items]
Additions other than through business combinations, property, plant and equipment	€ 535	1,592
Dupixent \| Manufacturing & Supply
Disclosure of detailed information about property, plant and equipment [line items]
Additions other than through business combinations, property, plant and equipment	366	1,188
Opella \| Manufacturing & Supply
Disclosure of detailed information about property, plant and equipment [line items]
Additions other than through business combinations, property, plant and equipment	41	90
Opella
Disclosure of detailed information about property, plant and equipment [line items]
Additions other than through business combinations, property, plant and equipment	€ 56	€ 101

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) € in Millions	6 Months Ended
	Jun. 30, 2024 EUR (€)
Property, plant and equipment [abstract]
Firm orders of property, plant and equipment	€ 659

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Additional Information (Details) - EUR (€) € in Millions		6 Months Ended
	May 10, 2024	Jun. 30, 2024	Dec. 31, 2023
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill		€ 50,080	€ 49,404
Carrying amount of intangible assets		26,653	24,319
Other intangible assets excluding software
Disclosure of reconciliation of changes in goodwill [line items]
Acquisitions and other increases		772
Other intangible assets excluding software \| Vaccines Co-exclusive licensing agreement \| Novavax
Disclosure of reconciliation of changes in goodwill [line items]
Acquisitions and other increases	€ 463
Marketed products
Disclosure of reconciliation of changes in goodwill [line items]
Carrying amount of intangible assets		€ 16,300	16,600
Weighted average amortization period		11 years
Technological platforms
Disclosure of reconciliation of changes in goodwill [line items]
Carrying amount of intangible assets		€ 1,400	€ 1,200
Weighted average amortization period		18 years

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Schedule of Movements in Other Intangible Assets (Details) - EUR (€) € in Millions		6 Months Ended		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disclosure of detailed information about intangible assets [line items]
Amortization expense		€ (1,061)	€ (1,035)	€ (2,172)
Carrying amount of intangible assets		26,653		24,319
Gross value
Disclosure of detailed information about intangible assets [line items]
Acquisitions and other increases		813
Disposals and retirements, intangible assets other than goodwill		(83)
Increase (decrease) through net exchange differences, intangible assets other than goodwill		1,293
Increase (decrease) through transfers, intangible assets other than goodwill		13
Carrying amount of intangible assets		89,115		85,313
Change In Scope Of Consolidation Through Business Combination, Intangible Assets	[1]	1,766
Accumulated amortization and impairment
Disclosure of detailed information about intangible assets [line items]
Disposals and retirements, intangible assets other than goodwill		82
Increase (decrease) through net exchange differences, intangible assets other than goodwill		(775)
Increase (decrease) through transfers, intangible assets other than goodwill		(5)
Amortization expense		1,136
Impairment losses, net of reversals	[2]	(366)
Other intangible assets, ending balance		26,653
Carrying amount of intangible assets		(62,462)		(60,994)	[1]
Acquired R&D
Disclosure of detailed information about intangible assets [line items]
Carrying amount of intangible assets				6,038
Acquired R&D \| Gross value
Disclosure of detailed information about intangible assets [line items]
Acquisitions and other increases		571
Disposals and retirements, intangible assets other than goodwill		(49)
Increase (decrease) through net exchange differences, intangible assets other than goodwill		236
Increase (decrease) through transfers, intangible assets other than goodwill		2
Carrying amount of intangible assets		12,298		9,772
Change In Scope Of Consolidation Through Business Combination, Intangible Assets	[1]	1,766
Acquired R&D \| Accumulated amortization and impairment
Disclosure of detailed information about intangible assets [line items]
Disposals and retirements, intangible assets other than goodwill		49
Increase (decrease) through net exchange differences, intangible assets other than goodwill		(70)
Increase (decrease) through transfers, intangible assets other than goodwill		0
Amortization expense		0
Impairment losses, net of reversals	[2]	13
Other intangible assets, ending balance		8,530
Carrying amount of intangible assets		(3,768)		(3,734)	[1]
Products, trademarks and other rights
Disclosure of detailed information about intangible assets [line items]
Carrying amount of intangible assets				17,825
Products, trademarks and other rights \| Gross value
Disclosure of detailed information about intangible assets [line items]
Acquisitions and other increases		201
Disposals and retirements, intangible assets other than goodwill		(27)
Increase (decrease) through net exchange differences, intangible assets other than goodwill		1,050
Increase (decrease) through transfers, intangible assets other than goodwill		12
Carrying amount of intangible assets		74,969		73,733
Change In Scope Of Consolidation Through Business Combination, Intangible Assets	[1]	0
Products, trademarks and other rights \| Accumulated amortization and impairment
Disclosure of detailed information about intangible assets [line items]
Disposals and retirements, intangible assets other than goodwill		27
Increase (decrease) through net exchange differences, intangible assets other than goodwill		(701)
Increase (decrease) through transfers, intangible assets other than goodwill		(4)
Amortization expense		1,084
Impairment losses, net of reversals	[2]	(379)
Other intangible assets, ending balance		17,678
Carrying amount of intangible assets		(57,291)		(55,908)	[1]
Software
Disclosure of detailed information about intangible assets [line items]
Carrying amount of intangible assets				456
Software \| Gross value
Disclosure of detailed information about intangible assets [line items]
Acquisitions and other increases		41
Disposals and retirements, intangible assets other than goodwill		(7)
Increase (decrease) through net exchange differences, intangible assets other than goodwill		7
Increase (decrease) through transfers, intangible assets other than goodwill		(1)
Carrying amount of intangible assets		1,848		1,808
Change In Scope Of Consolidation Through Business Combination, Intangible Assets	[1]	0
Software \| Accumulated amortization and impairment
Disclosure of detailed information about intangible assets [line items]
Disposals and retirements, intangible assets other than goodwill		6
Increase (decrease) through net exchange differences, intangible assets other than goodwill		(4)
Increase (decrease) through transfers, intangible assets other than goodwill		(1)
Amortization expense		52
Impairment losses, net of reversals	[2]	0
Other intangible assets, ending balance		445
Carrying amount of intangible assets		€ (1,403)		€ (1,352)	[1]

[1] Impact of the acquisition of Inhibrx, Inc (see Note B.1.).

Impairment of Intangible Asse_2

Impairment of Intangible Assets (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disclosure of impairment loss and reversal of impairment loss [abstract]
Impairment loss on other intangible assets	€ (371)	€ 15	€ 896

Investments Accounted for Usi_3

Investments Accounted for Using the Equity Method - Summary of Investments in Associates and Joint Ventures (Details) - EUR (€) € / shares in Units, € in Millions		6 Months Ended
		Jun. 30, 2024	Dec. 31, 2023
Disclosure of transactions between related parties [line items]
Investments accounted for using the equity method		€ 315	€ 424
Subordinated liabilities		€ 200
EUROAPI
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in associate	[1]	29.80%
Investments in associates	[1]	€ 72	€ 162
EUROAPI
Disclosure of transactions between related parties [line items]
Stock price (in euro per share)		€ 2.55	€ 5.73
MSP Vaccine Company \| MCM Vaccine BV
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in subsidiary		100%
Infraserv GmbH & Co. Höchst KG
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in joint venture	[2]	31.20%
Investments in joint ventures	[2]	€ 89	€ 90
MSP Vaccine Company
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in joint venture	[3]	50%
Investments in joint ventures	[3]	€ 90	96
Other investments
Disclosure of transactions between related parties [line items]
Proportion of ownership interest in joint venture		0%
Investments in joint ventures		€ 64	€ 76

[1] (a) The investment in EUROAPI includes an impairment loss determined by reference to the quoted market price (€2.55 as of June 30, 2024, and €5.73 as of December 31, 2023). Joint venture.

Investments Accounted for Usi_4

Investments Accounted for Using the Equity Method - Summary of Principal Transactions and Balances with Related Parties (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disclosure of transactions between related parties [line items]
Subordinated liabilities	€ 200
Associates and joint ventures
Disclosure of transactions between related parties [line items]
Sales	59	€ 64	€ 157
Royalties and other income	61	32	63
Accounts receivable and other receivables	278	213	249
Purchases of goods and services	345	302	642
Accounts payable and other payables	€ 63	€ 97	€ 71

Other Non-Current Assets (Detai

Other Non-Current Assets (Details) - EUR (€) € in Millions	Jun. 30, 2024	Dec. 31, 2023
Disclosure Of Other Non Current Assets [Line Items]
Other financial assets at fair value through profit or loss	€ 817	€ 808
Pre-funded pension obligations	325	271
Long-term prepaid expenses	95	114
Long-term loans and advances and other non-current receivables	587	591
Total	3,333	3,218
Trading equity securities
Disclosure Of Other Non Current Assets [Line Items]
Instruments at fair value through other comprehensive income	1,161	1,088
Debt securities
Disclosure Of Other Non Current Assets [Line Items]
Instruments at fair value through other comprehensive income	€ 347	€ 346

Accounts Receivable - Summary o

Accounts Receivable - Summary of Accounts Receivable (Details) - EUR (€) € in Millions	Jun. 30, 2024	Dec. 31, 2023
Disclosure of Accounts Receivable [Line Items]
Accounts receivable	€ 8,510	€ 8,433
Gross value
Disclosure of Accounts Receivable [Line Items]
Accounts receivable	8,602	8,528
Allowances
Disclosure of Accounts Receivable [Line Items]
Accounts receivable	€ 92	€ 95

Accounts Receivable - Additiona

Accounts Receivable - Additional Information (Details) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Trade and other receivables [abstract]
Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables	€ 3	€ 2
Derecognized receivables	€ 503		€ 761

Accounts Receivable - Summary_2

Accounts Receivable - Summary of Gross Value of Overdue Receivables (Details) - EUR (€) € in Millions	Jun. 30, 2024	Dec. 31, 2023
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	€ 646	€ 689
Overdue by less than 1 month
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	264	269
Overdue by 1-3 months
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	105	154
Overdue by 3-6 months
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	137	123
Overdue by 6-12 months
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	69	62
Overdue by > 12 months
Disclosure of Financial Assets that are Either Past Due or Impaired [Line Items]
Overdue receivables gross value	€ 71	€ 81

Consolidated Shareholders' Eq_3

Consolidated Shareholders' Equity - Additional Information (Details) - EUR (€)			6 Months Ended		12 Months Ended
	Apr. 30, 2024	May 25, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jun. 24, 2024	Jan. 31, 2024	Jun. 23, 2023	Feb. 02, 2023
Disclosure of classes of share capital [Line Items]
Share capital			€ 2,532,725,512
Number of shares (in shares)			1,266,362,756
Par value per share (in euros per share)			€ 2
Number of restricted shares vested (in shares)			2,803,637
Number of restricted shares alloted in regards of capital increase			1,332,205
Other comprehensive income that will be reclassified to profit or loss, net of tax			€ 1,067,000,000	€ (1,058,000,000)	€ (1,526,000,000)
Employees share ownership plan
Disclosure of classes of share capital [Line Items]
Subscription price (in euros per share)							€ 72.87		€ 79.58
Number of shares subscribed (in shares)						2,124,445		2,009,306
Number of shares issued immediately for employer's contribution (in shares)						119,951		119,417
Expense recognized			€ 45,000,000	52,000,000
Share Repurchase 2023 program
Disclosure of classes of share capital [Line Items]
Period of share repurchase program		18 months
Number of shares repurchased (in shares)			3,215,460
Amount of shares repurchased			€ 302,000,000
Share Repurchase 2024 Program
Disclosure of classes of share capital [Line Items]
Period of share repurchase program	18 months
Share capital \| Sanofi
Disclosure of classes of share capital [Line Items]
Capital increase by exercise of stock subscription options (in shares)			91,355
Capital increase by issuance of restricted shares (in shares)			1,471,432
Other comprehensive income \| Items subsequently reclassifiable to profit or loss
Disclosure of classes of share capital [Line Items]
Other comprehensive income that will be reclassified to profit or loss, net of tax			€ 1,067,000,000	(1,058,000,000)	(1,526,000,000)
Other comprehensive income \| Foreign Currency Translation \| Items subsequently reclassifiable to profit or loss
Disclosure of classes of share capital [Line Items]
Other comprehensive income that will be reclassified to profit or loss, net of tax				€ (14,000,000)	€ (56,000,000)

Consolidated Shareholders' Eq_4

Consolidated Shareholders' Equity - Summary of Treasury Shares Held (Details) - shares shares in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Share Capital, Reserves And Other Equity Interest [Abstract]
Number of shares (in shares)	15,330	13,450	10,900	8,200
% of share capital for the period	1.211%	1.063%	0.864%	0.65%

Consolidated Shareholders' Eq_5

Consolidated Shareholders' Equity - Summary of Principal Characteristics of Restricted Share Plans (Details) € / shares in Units, € in Millions	6 Months Ended
	Jun. 30, 2024 EUR (€) shares € / shares
Restricted Share Plan 2024
Disclosure of classes of share capital [Line Items]
Total number of shares awarded (in shares)	4,505,145
Fair value of plan at the date of grant \| €	€ 346
Service period	3 years
Restricted Share Plan 2024 \| Without market condition
Disclosure of classes of share capital [Line Items]
Total number of shares awarded (in shares)	2,888,502
Fair value per share awarded (in euros per share) \| € / shares	€ 81.84	[1]
Restricted Share Plan 2024 \| With market condition
Disclosure of classes of share capital [Line Items]
Total number of shares awarded (in shares)	1,616,643
Restricted Share Plan 2024 \| With market condition \| Excluding General Director
Disclosure of classes of share capital [Line Items]
Total number of shares awarded (in shares)	1,394,478
Fair value per share awarded (in euros per share) \| € / shares	€ 72.79	[2]
Restricted Share Plan 2024 \| With market condition \| Chief Executive Officer
Disclosure of classes of share capital [Line Items]
Total number of shares awarded (in shares)	82,500
Fair value per share awarded (in euros per share) \| € / shares	€ 72.38	[2]
Restricted Share Plan 2024, Additional Shares \| With market condition \| Excluding General Director
Disclosure of classes of share capital [Line Items]
Total number of shares awarded (in shares)	139,665
Fair value per share awarded (in euros per share) \| € / shares	€ 13.50	[3]

[1] Quoted market price per share at the date of grant, adjusted for dividends expected during the vesting period. (b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.

Consolidated Shareholders' Eq_6

Consolidated Shareholders' Equity - Summary of Number of Restricted Shares Not Yet Fully Vested (Details) - EUR (€) € in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Restricted shares
Disclosure of classes of share capital [Line Items]
Total expense for restricted share plans	€ 128	€ 108
Number of shares not yet fully vested (in shares)	11,192,984	10,127,545
Restricted share plan 2023
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	3,652,352	3,837,974
Restricted share plan 2022
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	3,031,060	3,226,321
Restricted share plan 2021
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	11,463	2,996,101
Restricted share plan 2020
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	0	67,149
Restricted Share Plan 2024
Disclosure of classes of share capital [Line Items]
Number of shares not yet fully vested (in shares)	4,498,109	0

Consolidated Shareholders' Eq_7

Consolidated Shareholders' Equity - Summary of Options Outstanding and Exercisable (Details) - Stock Option Plan	6 Months Ended
	Jun. 30, 2024 shares € / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, number of options (in shares) \| shares	1,241,658
Exercisable, number of options (in shares) \| shares	1,241,658
From €60.00 to €70.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, number of options (in shares) \| shares	168,784
Weighted average residual life (years)	3 years 10 months 2 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)	€ 65.84
Exercisable, number of options (in shares) \| shares	168,784
Weighted average exercise price per share, options exercisable (in euros per share)	€ 65.84
From €70.00 to €80.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, number of options (in shares) \| shares	478,150
Weighted average residual life (years)	3 years 2 months 4 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)	€ 76.26
Exercisable, number of options (in shares) \| shares	478,150
Weighted average exercise price per share, options exercisable (in euros per share)	€ 76.26
From €80.00 to €90.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding, number of options (in shares) \| shares	594,724
Weighted average residual life (years)	1 year 9 months 14 days
Weighted average exercise price of share options outstanding in share-based payment arrangement (in euros per share)	€ 89.20
Exercisable, number of options (in shares) \| shares	594,724
Weighted average exercise price per share, options exercisable (in euros per share)	€ 89.20
Bottom of range \| From €60.00 to €70.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	60
Bottom of range \| From €70.00 to €80.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	70
Bottom of range \| From €80.00 to €90.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	80
Top of range \| From €60.00 to €70.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	70
Top of range \| From €70.00 to €80.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	80
Top of range \| From €80.00 to €90.00 per share
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of outstanding options (in euros per share)	€ 90

Consolidated Shareholders' Eq_8

Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details) - shares shares in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Share Capital, Reserves And Other Equity Interest [Abstract]
Average number of shares outstanding (in shares)	1,249.4	1,249.9	1,251.7
Adjustment for stock options with dilutive effect (in shares)	0.1	0.3	0.2
Adjustment for restricted shares (in shares)	4.3	4.3	4.5
Average number of shares used to compute diluted earnings per share (in shares)	1,253.8	1,254.5	1,256.4

Consolidated Shareholders' Eq_9

Consolidated Shareholders' Equity - Summary of Movements within Other Comprehensive Income (Details) - EUR (€) € in Millions		6 Months Ended		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disclosure of analysis of other comprehensive income by item [Line Items]
Items not subsequently reclassifiable to profit or loss		€ 166	€ 85	€ (77)
Items subsequently reclassifiable to profit or loss		1,067	(1,058)	(1,526)
Accumulated other comprehensive income \| Items not subsequently reclassifiable to profit or loss
Disclosure of analysis of other comprehensive income by item [Line Items]
Actuarial gains/(losses) excluding investments accounted for using the equity method		235	133	(171)
Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes		0	8	0
Tax effects		(57)	(60)	18
Items not subsequently reclassifiable to profit or loss		166	85	(77)
Accumulated other comprehensive income \| Items not subsequently reclassifiable to profit or loss \| Equity instruments included in financial assets
Disclosure of analysis of other comprehensive income by item [Line Items]
Change in fair value (excluding investments accounted for using the equity method)		(10)	3	97
Change in fair value (investments accounted for using the equity method, net of taxes)		0	0	0
Equity risk hedging instruments designated as fair value hedges		0	0	0
Tax effects		(2)	1	(21)
Accumulated other comprehensive income \| Items subsequently reclassifiable to profit or loss
Disclosure of analysis of other comprehensive income by item [Line Items]
Change in fair value (excluding investments accounted for using the equity method)	[1]	(4)	1	1
Change in fair value (investments accounted for using the equity method, net of taxes)		1	0	(2)
Tax effects		1	0	0
Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)	[2]	1,167	(1,089)	(1,551)
Currency translation differences (investments accounted for using the equity method)		(1)	6	3
Hedges of net investments in foreign operations		(126)	26	8
Tax effects		33	(7)	(2)
Items subsequently reclassifiable to profit or loss		1,067	(1,058)	(1,526)
Accumulated other comprehensive income \| Items subsequently reclassifiable to profit or loss \| Debt instruments included in financial assets
Disclosure of analysis of other comprehensive income by item [Line Items]
Change in fair value (excluding investments accounted for using the equity method)	[3]	(5)	6	21
Change in fair value (investments accounted for using the equity method, net of taxes)		0	0	0
Tax effects		€ 1	(1)	(4)
Accumulated other comprehensive income \| Items subsequently reclassifiable to profit or loss \| Foreign Currency Translation
Disclosure of analysis of other comprehensive income by item [Line Items]
Items subsequently reclassifiable to profit or loss			€ (14)	€ (56)

[1] Includes reclassifications to profit or loss: immaterial over all periods. Currency translation differences on foreign subsidiaries are mainly due to the appreciation of the US dollar. Includes a reclassification to profit or loss: immaterial in the first half of 2024 , €(56) million in 2023 and €(14) million in the first half of 2023. Includes reclassifications to profit or loss: immaterial over all periods.

Debt, Cash and Cash Equivalen_3

Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details) - EUR (€) € in Millions		Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Cash and cash equivalents [abstract]
Long-term debt		€ 12,503	€ 14,347
Short-term debt and current portion of long-term debt		9,236	2,045
Interest rate and currency derivatives used to manage debt		179	139
Total debt		21,918	16,531
Cash and cash equivalents		(6,795)	(8,710)	€ (7,993)	€ (12,736)
Interest rate and currency derivatives used to manage cash and cash equivalents		(11)	(28)
Net debt	[1]	15,112	7,793
Lease liabilities		€ 2,012	€ 2,030

[1]Net debt does not include lease liabilities, which amounted to €2,012 million as of June 30, 2024 and €2,030 million as of December 31, 2023

Debt, Cash and Cash Equivalen_4

Debt, Cash and Cash Equivalents - Summary of Reconciliation of Carrying Amount to Value on Redemption (Details) - EUR (€) € in Millions		Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt		€ 12,503	€ 14,347
Short-term debt and current portion of long-term debt		9,236	2,045
Interest rate and currency derivatives used to manage debt		179	139
Total debt		21,918	16,531
Cash and cash equivalents		(6,795)	(8,710)	€ (7,993)	€ (12,736)
Interest rate and currency derivatives used to manage cash and cash equivalents		(11)	(28)
Net debt	[1]	15,112	7,793
Lease liabilities		2,012	2,030
Amortized cost
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt		35
Short-term debt and current portion of long-term debt		0
Interest rate and currency derivatives used to manage debt		0
Total debt		35
Cash and cash equivalents		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0
Net debt	[2]	35
Adjustment to debt measured at fair value
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt		150
Short-term debt and current portion of long-term debt		18
Interest rate and currency derivatives used to manage debt		(169)
Total debt		(1)
Cash and cash equivalents		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0
Net debt	[2]	(1)
Value on redemption
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Long-term debt		12,688	14,546
Short-term debt and current portion of long-term debt		9,254	2,045
Interest rate and currency derivatives used to manage debt		10	(18)
Total debt		21,952	16,573
Cash and cash equivalents		(6,795)	(8,710)
Interest rate and currency derivatives used to manage cash and cash equivalents		(11)	(28)
Net debt	[2]	€ 15,146	€ 7,835

[1]Net debt does not include lease liabilities, which amounted to €2,012 million as of June 30, 2024 and €2,030 million as of December 31, 2023[2]Net debt does not include lease liabilities, which amounted to €2,012 million as of June 30, 2024 and €2,030 million as of December 31, 2023

Debt, Cash and Cash Equivalen_5

Debt, Cash and Cash Equivalents - Summary of Net Debt by Type Valuation of Redemption (Details) - EUR (€) € in Millions		Jun. 30, 2024		Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Interest rate and currency derivatives used to manage debt		€ 179		€ 139
Total debt		21,918		16,531
Cash and cash equivalents		(6,795)		(8,710)	€ (7,993)	€ (12,736)
Interest rate and currency derivatives used to manage cash and cash equivalents		(11)		(28)
Net debt	[1]	15,112		7,793
Value on redemption
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues		14,509		15,134
Other bank borrowings		7,213		1,248
Other borrowings		5		6
Bank credit balances		215		203
Interest rate and currency derivatives used to manage debt		10		(18)
Total debt		21,952		16,573
Cash and cash equivalents		(6,795)		(8,710)
Interest rate and currency derivatives used to manage cash and cash equivalents		(11)		(28)
Net debt	[2]	15,146		7,835
Value on redemption \| non-current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Cash and cash equivalents		0		0
Interest rate and currency derivatives used to manage cash and cash equivalents		0		0
Net debt		12,688		14,546
Value on redemption \| current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Cash and cash equivalents		(6,795)		(8,710)
Interest rate and currency derivatives used to manage cash and cash equivalents		(11)		(28)
Net debt		2,458		(6,711)
Value on redemption \| non-current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues		12,593		14,416
Other bank borrowings		95		130
Other borrowings		0		0
Bank credit balances		0		0
Interest rate and currency derivatives used to manage debt		0		0
Total debt		12,688		14,546
Value on redemption \| current
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Bond issues		1,916		718
Other bank borrowings		7,118	[3]	1,118
Other borrowings		5		6
Bank credit balances		215		203
Interest rate and currency derivatives used to manage debt		10		(18)
Total debt		9,264		€ 2,027
Value on redemption \| current \| Commercial paper program in USA
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Other bank borrowings		6,955
Value on redemption \| current \| Commercial paper program in France
Disclosure of reconciliation of carrying amount to value on redemption [line items]
Other bank borrowings		€ 0

[1]Net debt does not include lease liabilities, which amounted to €2,012 million as of June 30, 2024 and €2,030 million as of December 31, 2023[2]Net debt does not include lease liabilities, which amounted to €2,012 million as of June 30, 2024 and €2,030 million as of December 31, 2023[3] (a) As of June 30, 2024, current other bank borrowings includ

Debt, Cash and Cash Equivalen_6

Debt, Cash and Cash Equivalents - Additional Information (Details) - 6 months ended Jun. 30, 2024 € in Billions, $ in Billions	EUR (€)	USD ($)	USD ($)
Syndicated credit facility, expires in 2027
Disclosure of detailed information about borrowings [Line Items]
Notional amount	€ 4
Commercial paper program in France
Disclosure of detailed information about borrowings [Line Items]
Commercial paper programs	6
Commercial paper program in France \| Sanofi Euro Medium Term Notes
Disclosure of detailed information about borrowings [Line Items]
Borrowing, average drawdown	0.1
Commercial paper program in USA
Disclosure of detailed information about borrowings [Line Items]
Commercial paper programs \| $			$ 10
Commercial paper program in USA \| Sanofi Euro Medium Term Notes
Disclosure of detailed information about borrowings [Line Items]
Borrowing, average drawdown \| $		$ 5.8
Fixed Rate Bond Maturing April2024 Redeemed2024 \| Sanofi Euro Medium Term Notes
Disclosure of detailed information about borrowings [Line Items]
Notional amount	€ 0.6

Debt, Cash and Cash Equivalen_7

Debt, Cash and Cash Equivalents - Summary of Market Value of Net Debt (Details) - EUR (€) € in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Disclosure of detailed information about borrowings [Line Items]
Market value	€ 21,918	€ 16,531
Market value
Disclosure of detailed information about borrowings [Line Items]
Market value	14,214	7,086
Value on redemption
Disclosure of detailed information about borrowings [Line Items]
Market value	21,952	16,573
Value on redemption	€ 15,146	€ 7,835

Derivative Financial Instrume_3

Derivative Financial Instruments - Summary of Operating Currency Hedging Instruments (Details) € in Millions	Jun. 30, 2024 EUR (€)
Notional amount
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	€ 8,315
Notional amount \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	5,120
Notional amount \| Forward currency sales in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	2,152
Notional amount \| Forward currency sales in Chinese yuan renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	608
Notional amount \| Forward currency sales in Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	269
Notional amount \| Forward currency sales in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	197
Notional amount \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	3,195
Notional amount \| Forward currency purchases in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1,733
Notional amount \| Forward currency purchases in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	398
Notional amount \| Forward currency purchases in Canadian dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	100
Notional amount \| Forward Currency Sales In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	252
Notional amount \| Forward Currency Purchases In Turkish lira
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	108
Notional amount \| Forward Currency Purchases In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	203
Notional amount \| Cash flow hedges
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency sales in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency sales in Chinese yuan renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency sales in Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency sales in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency purchases in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency purchases in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward currency purchases in Canadian dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward Currency Sales In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward Currency Purchases In Turkish lira
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Cash flow hedges \| Forward Currency Purchases In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Notional amount \| Not eligible for hedge accounting
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	8,315
Notional amount \| Not eligible for hedge accounting \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	5,120
Notional amount \| Not eligible for hedge accounting \| Forward currency sales in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	2,152
Notional amount \| Not eligible for hedge accounting \| Forward currency sales in Chinese yuan renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	608
Notional amount \| Not eligible for hedge accounting \| Forward currency sales in Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	269
Notional amount \| Not eligible for hedge accounting \| Forward currency sales in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	197
Notional amount \| Not eligible for hedge accounting \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	3,195
Notional amount \| Not eligible for hedge accounting \| Forward currency purchases in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1,733
Notional amount \| Not eligible for hedge accounting \| Forward currency purchases in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	398
Notional amount \| Not eligible for hedge accounting \| Forward currency purchases in Canadian dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	100
Notional amount \| Not eligible for hedge accounting \| Forward Currency Sales In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	252
Notional amount \| Not eligible for hedge accounting \| Forward Currency Purchases In Turkish lira
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	108
Notional amount \| Not eligible for hedge accounting \| Forward Currency Purchases In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	203
Fair value
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(24)
Fair value \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(45)
Fair value \| Forward currency sales in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(17)
Fair value \| Forward currency sales in Chinese yuan renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Forward currency sales in Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	5
Fair value \| Forward currency sales in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(1)
Fair value \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	21
Fair value \| Forward currency purchases in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	2
Fair value \| Forward currency purchases in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1
Fair value \| Forward currency purchases in Canadian dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1
Fair value \| Forward Currency Sales In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(31)
Fair value \| Forward Currency Purchases In Turkish lira
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	7
Fair value \| Forward Currency Purchases In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	12
Fair value \| Cash flow hedges
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency sales in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency sales in Chinese yuan renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency sales in Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency sales in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency purchases in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency purchases in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward currency purchases in Canadian dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward Currency Sales In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward Currency Purchases In Turkish lira
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Cash flow hedges \| Forward Currency Purchases In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Not eligible for hedge accounting
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(24)
Fair value \| Not eligible for hedge accounting \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(45)
Fair value \| Not eligible for hedge accounting \| Forward currency sales in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(17)
Fair value \| Not eligible for hedge accounting \| Forward currency sales in Chinese yuan renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Fair value \| Not eligible for hedge accounting \| Forward currency sales in Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	5
Fair value \| Not eligible for hedge accounting \| Forward currency sales in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(1)
Fair value \| Not eligible for hedge accounting \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	21
Fair value \| Not eligible for hedge accounting \| Forward currency purchases in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	2
Fair value \| Not eligible for hedge accounting \| Forward currency purchases in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1
Fair value \| Not eligible for hedge accounting \| Forward currency purchases in Canadian dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	1
Fair value \| Not eligible for hedge accounting \| Forward Currency Sales In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	(31)
Fair value \| Not eligible for hedge accounting \| Forward Currency Purchases In Turkish lira
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	7
Fair value \| Not eligible for hedge accounting \| Forward Currency Purchases In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	12
Value of hedge recognized in equity \| Cash flow hedges
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Value of hedge recognized in equity \| Cash flow hedges \| Forward currency sales
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Value of hedge recognized in equity \| Cash flow hedges \| Forward currency sales in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Value of hedge recognized in equity \| Cash flow hedges \| Forward currency sales in Chinese yuan renminbi
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Value of hedge recognized in equity \| Cash flow hedges \| Forward currency sales in Japanese yen
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Value of hedge recognized in equity \| Cash flow hedges \| Forward currency sales in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Value of hedge recognized in equity \| Cash flow hedges \| Forward currency purchases
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Value of hedge recognized in equity \| Cash flow hedges \| Forward currency purchases in US dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Value of hedge recognized in equity \| Cash flow hedges \| Forward currency purchases in Singapore dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Value of hedge recognized in equity \| Cash flow hedges \| Forward currency purchases in Canadian dollar
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Value of hedge recognized in equity \| Cash flow hedges \| Forward Currency Sales In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Value of hedge recognized in equity \| Cash flow hedges \| Forward Currency Purchases In Turkish lira
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	0
Value of hedge recognized in equity \| Cash flow hedges \| Forward Currency Purchases In Russian rouble
Disclosure of Information about Credit Exposures Designated as Measured at Fair Value Through Profit or Loss [Line Items]
Operating currency hedging instruments in place	€ 0

Derivative Financial Instrume_4

Derivative Financial Instruments - Disclosure of Financial Currency Hedging Instruments in Place with Notional Amount Translated (Details) € in Millions, $ in Millions		6 Months Ended		12 Months Ended
		Jun. 30, 2024 EUR (€)	Jun. 30, 2023 EUR (€)	Dec. 31, 2023 EUR (€)	Jun. 30, 2024 USD ($)
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Change in fair value of cash flow hedges		€ (3)	€ 1	€ (1)
Forward currency sales in US dollar
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Notional amount \| $					$ 3,615
Derivative financial liabilities		26
Forward currency purchases in US dollar, US bond
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Notional amount \| $					1,000
Derivative financial liabilities		2
Change in fair value of cash flow hedges		0
Forward currency purchases in US dollar, commercial paper
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Notional amount \| $					$ 1,080
Derivative financial assets		16
Change in fair value of cash flow hedges		0
Notional amount
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		14,846
Notional amount \| Forward currency sales
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		7,190
Notional amount \| Forward currency sales in US dollar \| 2025
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	[1]	5,797
Notional amount \| Forward currency purchases
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		7,656
Notional amount \| Forward currency purchases in US dollar \| 2025
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place	[2],[3]	5,242
Notional amount \| Forward currency purchases in Singapore dollar \| 2024
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		1,768
Notional amount \| Forward currency sales in Chinese yuan renminbi \| 2024
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		301
Notional amount \| Forward Currency Sales In Canadian Dollar \| 2024
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		190
Notional amount \| Forward Currency Purchases In Hungarian florint \| 2024
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		182
Fair value
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		12
Fair value \| Forward currency sales
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		(30)
Fair value \| Forward currency sales in US dollar \| 2025
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		(28)
Fair value \| Forward currency purchases
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		42
Fair value \| Forward currency purchases in US dollar \| 2025
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		37
Fair value \| Forward currency purchases in Singapore dollar \| 2024
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		7
Fair value \| Forward currency sales in Chinese yuan renminbi \| 2024
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		(1)
Fair value \| Forward Currency Sales In Canadian Dollar \| 2024
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		(1)
Fair value \| Forward Currency Purchases In Hungarian florint \| 2024
Disclosure of Information about Terms and Conditions of Hedging Instruments and How They Affect Future Cash Flows [Line Items]
Financial currency hedging instruments in place		€ (1)

[1] Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi’s net investment in Bioverativ. As of June 30, 2024, the fair value of these forward contracts represented a liability of €26 million; the opposite entry was recognized in “Other comprehensive income”, with the impact on financial income and expense being immaterial. (b) Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to

Derivative Financial Instrume_5

Derivative Financial Instruments - Disclosure of Instruments (Details) € in Millions	Jun. 30, 2024 EUR (€)
Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 3,431
Notional amount \| Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	3,431
Notional amount \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Notional amount \| 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	997
Notional amount \| 2025
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	850
Notional amount \| 2026
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Notional amount \| 2027
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Notional amount \| 2028 and beyond
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	1,584
Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(181)
Fair value \| Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(181)
Fair value \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Value of hedge recognized in equity \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 0
pay capitalized SOFR USD / receive 1.32%
Disclosure of detailed information about financial instruments [line items]
Interest rate	1.32%
pay capitalized SOFR USD / receive 1.32% \| Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 467
pay capitalized SOFR USD / receive 1.32% \| Notional amount \| Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	467
pay capitalized SOFR USD / receive 1.32% \| Notional amount \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized SOFR USD / receive 1.32% \| Notional amount \| 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized SOFR USD / receive 1.32% \| Notional amount \| 2025
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized SOFR USD / receive 1.32% \| Notional amount \| 2026
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized SOFR USD / receive 1.32% \| Notional amount \| 2027
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized SOFR USD / receive 1.32% \| Notional amount \| 2028 and beyond
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	467
pay capitalized SOFR USD / receive 1.32% \| Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(48)
pay capitalized SOFR USD / receive 1.32% \| Fair value \| Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(48)
pay capitalized SOFR USD / receive 1.32% \| Fair value \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized SOFR USD / receive 1.32% \| Value of hedge recognized in equity \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 0
pay capitalized Ester / receive 0.69%
Disclosure of detailed information about financial instruments [line items]
Interest rate	0.69%
pay capitalized Ester / receive 0.69% \| Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 850
pay capitalized Ester / receive 0.69% \| Notional amount \| Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	850
pay capitalized Ester / receive 0.69% \| Notional amount \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Ester / receive 0.69% \| Notional amount \| 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Ester / receive 0.69% \| Notional amount \| 2025
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	850
pay capitalized Ester / receive 0.69% \| Notional amount \| 2026
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Ester / receive 0.69% \| Notional amount \| 2027
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Ester / receive 0.69% \| Notional amount \| 2028 and beyond
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Ester / receive 0.69% \| Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(24)
pay capitalized Ester / receive 0.69% \| Fair value \| Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(24)
pay capitalized Ester / receive 0.69% \| Fair value \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Ester / receive 0.69% \| Value of hedge recognized in equity \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 0
pay capitalized Ester / receive 0.92%
Disclosure of detailed information about financial instruments [line items]
Interest rate	0.92%
pay capitalized Ester / receive 0.92% \| Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 650
pay capitalized Ester / receive 0.92% \| Notional amount \| Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	650
pay capitalized Ester / receive 0.92% \| Notional amount \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Ester / receive 0.92% \| Notional amount \| 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Ester / receive 0.92% \| Notional amount \| 2025
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Ester / receive 0.92% \| Notional amount \| 2026
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Ester / receive 0.92% \| Notional amount \| 2027
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Ester / receive 0.92% \| Notional amount \| 2028 and beyond
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	650
pay capitalized Ester / receive 0.92% \| Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(56)
pay capitalized Ester / receive 0.92% \| Fair value \| Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(56)
pay capitalized Ester / receive 0.92% \| Fair value \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
pay capitalized Ester / receive 0.92% \| Value of hedge recognized in equity \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 0
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02%
Disclosure of detailed information about financial instruments [line items]
Interest rate	1.02%
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% \| Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 467
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% \| Notional amount \| Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	467
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% \| Notional amount \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% \| Notional amount \| 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% \| Notional amount \| 2025
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% \| Notional amount \| 2026
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% \| Notional amount \| 2027
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% \| Notional amount \| 2028 and beyond
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	467
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% \| Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(53)
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% \| Fair value \| Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	(53)
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% \| Fair value \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized SOFR USD / Receive 1.02% \| Value of hedge recognized in equity \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 0
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56%
Disclosure of detailed information about financial instruments [line items]
Interest rate	3.56%
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% \| Notional amount
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 997
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% \| Notional amount \| Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	997
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% \| Notional amount \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% \| Notional amount \| 2024
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	997
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% \| Notional amount \| 2025
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% \| Notional amount \| 2026
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% \| Notional amount \| 2027
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% \| Notional amount \| 2028 and beyond
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% \| Fair value
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% \| Fair value \| Fair value hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% \| Fair value \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	0
Interest Rate Swaps Pay Capitalized Ester / Receive 3.56% \| Value of hedge recognized in equity \| Cash flow hedges
Disclosure of detailed information about financial instruments [line items]
Currency and interest rate derivatives	€ 0

Liabilities Related to Busine_2

Liabilities Related to Business Combinations and to Non-Controlling Interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details) - EUR (€) € in Millions		6 Months Ended
		Jun. 30, 2024		Dec. 31, 2023
Disclosure of contingent liabilities in business combination [abstract]
Liabilities Related to Business Combinations and to Non-Controlling Interests		B.11. LIABILITIES RELATED TO BUSINESS COMBINATIONS AND TO NON-CONTROLLING INTERESTS For a description of the nature of the liabilities reported in the line item Liabilities related to business combinations and to non-controlling interests , refer to Note B.8.4. to the consolidated financial statements for the year ended December 31, 2023. The liabilities related to business combinations and to non-controlling interests shown in the table below are level 3 instruments under the IFRS 13 and IFRS 7 fair value hierarchy (see Note A.5.). Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2024 are shown below: (€ million) MSD contingent consideration (European Vaccines business) Shire contingent consideration arising from acquisition of Translate Bio Contingent consideration arising from acquisition of Amunix Other Total (a) Balance at January 1, 2024 127 441 137 4 709 Payments made (71) — — — (71) Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (b) 4 71 — — 75 Other movements — — — (3) (3) Currency translation differences 1 14 3 — 18 Balance at June 30, 2024 61 526 140 1 728 Of which: • Current portion 201 • Non-current portion 527 (a) As of January 1, 2024, this comprised a non-current portion of €501 million and a current portion of €208 million. (b) Amounts mainly reported within the income statement line item “Fair value remeasurement of contingent consideration”. As of June 30, 2024, Liabilities related to business combinations and to non-controlling interests mainly comprised: • The MSD contingent consideration liability arising from the 2016 acquisition of the Sanofi Pasteur activities carried on within the former Sanofi Pasteur MSD joint venture, which amounted to €61 million as of June 30, 2024 versus €127 million as of December 31, 2023. The fair value of this contingent consideration is determined by applying the royalty percentage stipulated in the contract to discounted projections of sales by Sanofi through December 31, 2024 of products previously commercialized by the joint venture. If the discount rate were to fall by one percentage point, the fair value of the MSD contingent consideration would increase by approximately 1%; • The contingent consideration liability towards Shire Human Genetic Therapies Inc. (Shire) arising from Sanofi's acquisition of Translate Bio in September 2021. The fair value of the Shire liability is determined by applying the contractual terms to development and sales projections that are weighted to reflect the probability of success, and discounted. The liability was measured at €526 million as of June 30, 2024, compared with €441 million as of December 31, 2023. If the discount rate were to fall by one percentage point, the fair value of the Shire liability would increase by approximately 14%; and • The contingent consideration liability arising from the 2022 acquisition of Amunix. The fair value of the liability is determined on the basis of the nominal value of payments due subject to the attainment of specified development milestones . The liability was measured at €140 million
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance	[1]	€ 709
Payments made	[1]	(71)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	[1],[2]	75
Other movements	[1]	(3)
Currency translation differences	[1]	18
Ending balance	[1]	728
Current portion		201	[1]	€ 208
Non-current portion		527	[1]	€ 501
MSD contingent consideration (European Vaccines business)
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance		127
Payments made		(71)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	[2]	4
Other movements		0
Currency translation differences		1
Ending balance		61
Shire contingent consideration arising from acquisition of Translate Bio
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance		441
Payments made		0
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	[2]	71
Other movements		0
Currency translation differences		14
Ending balance		526
Contingent consideration arising from acquisition of Amunix
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance		137
Payments made		0
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	[2]	0
Other movements		0
Currency translation differences		3
Ending balance		140
Other
Changes In Liabilities Related To Business Combinations And Non-Controlling Interests [Roll Forward]
Beginning balance		4
Payments made		0
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)	[2]	0
Other movements		(3)
Currency translation differences		0
Ending balance		€ 1

[1] As of January 1, 2024, this comprised a non-current portion of €501 million and a current portion of €208 million.

Liabilities Related to Busine_3

Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details) - EUR (€) € in Millions		Jun. 30, 2024	Dec. 31, 2023
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Fair value of contingent consideration payable	[1]	€ 728	€ 709
MSD contingent consideration (European Vaccines business)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Fair value of contingent consideration payable		€ 61	127
Increase in fair value of liability		1%
Shire contingent consideration arising from acquisition of Translate Bio
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Fair value of contingent consideration payable		€ 526	441
Increase in fair value of liability		14%
Contingent consideration arising from acquisition of Amunix
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items]
Fair value of contingent consideration payable		€ 140	€ 137

[1] As of January 1, 2024, this comprised a non-current portion of €501 million and a current portion of €208 million.

Non-Current Provisions And Ot_3

Non-Current Provisions And Other Non-Current Liabilities - Summary of Non-Current Provisions and Other Non-Current Liabilities (Details) - EUR (€) € in Millions		Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Disclosure Of Non-current Provisions [Line Items]
Provisions		€ 5,918	€ 5,262	€ 5,018
Other non-current liabilities	[1]	2,301	2,340	2,070
Non-current provisions		8,219	€ 7,602	€ 7,088
Antibodies Collaboration Agreement \| Swedish Orphan Biovitrum AB
Disclosure Of Non-current Provisions [Line Items]
Other non-current liabilities		1,970
Antibodies Collaboration Agreement \| Swedish Orphan Biovitrum AB \| Later than one year and not later than five years [member]
Disclosure Of Non-current Provisions [Line Items]
Other non-current liabilities		1,147
Antibodies Collaboration Agreement \| Swedish Orphan Biovitrum AB \| Total
Disclosure Of Non-current Provisions [Line Items]
Other non-current liabilities		€ 2,679

[1]a) Includes €1,970 million at June 30, 2024 relating to the liability for royalties payable to Sobi on net sales of Beyfortus in the United States. Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five years is €1,147 million; the nominal value of payments estimated to be due after more than five years is €2,679 million

Non-Current Provisions And Ot_4

Non-Current Provisions And Other Non-Current Liabilities - Summary of Movements in Non-Current Provisions (Details) € in Millions	6 Months Ended
	Jun. 30, 2024 EUR (€)
Reconciliation of changes in other provisions [abstract]
Beginning balance	€ 5,262
Increases in provisions and other liabilities	(1,301)
Provisions utilized	230
Transfers	(122)	[1]
Net interest related to employee benefits, and unwinding of discount	60
Net interest related to employee benefits, and unwinding of discount	(119)
Currency translation differences	1
Actuarial gains and losses on defined-benefit plans (B.12.1.)	(235)
Ending balance	5,918
Provisions for pensions & other post-employment benefits
Reconciliation of changes in other provisions [abstract]
Beginning balance	2,214
Increases in provisions and other liabilities	(72)	[2]
Provisions utilized	78	[2]
Transfers	75	[1]
Net interest related to employee benefits, and unwinding of discount	37
Net interest related to employee benefits, and unwinding of discount	(63)	[2]
Currency translation differences	18
Actuarial gains and losses on defined-benefit plans (B.12.1.)	(235)
Ending balance	2,040
Provisions for other long-term benefits
Reconciliation of changes in other provisions [abstract]
Beginning balance	718
Increases in provisions and other liabilities	(89)
Provisions utilized	65
Transfers	0	[1]
Net interest related to employee benefits, and unwinding of discount	3
Net interest related to employee benefits, and unwinding of discount	1
Currency translation differences	13
Actuarial gains and losses on defined-benefit plans (B.12.1.)	0
Ending balance	759
Restructuring provisions
Reconciliation of changes in other provisions [abstract]
Beginning balance	554
Increases in provisions and other liabilities	(581)
Provisions utilized	11
Transfers	(173)	[1]
Net interest related to employee benefits, and unwinding of discount	9
Net interest related to employee benefits, and unwinding of discount	(4)
Currency translation differences	(47)
Actuarial gains and losses on defined-benefit plans (B.12.1.)	0
Ending balance	909
Other provisions
Reconciliation of changes in other provisions [abstract]
Beginning balance	1,776
Increases in provisions and other liabilities	(559)
Provisions utilized	76
Transfers	(24)	[1]
Net interest related to employee benefits, and unwinding of discount	11
Net interest related to employee benefits, and unwinding of discount	(53)
Currency translation differences	17
Actuarial gains and losses on defined-benefit plans (B.12.1.)	0
Ending balance	€ 2,210

[1](b) Mainly transfers to the line “Current provisions and other current liabilities[2] (a) In the case of “Provisions for pensions and other post-employment benefits”, the “Increases in provisions” line corresponds to rights vesting in employees during the period, and past service cost; the “Provisions utilized” line corresponds to contributions paid into pension funds and to beneficiaries; and the “Reversals of unutilized provisions” line corresponds to plan curtailments, settlements and amendments.

Non-Current Provisions And Ot_5

Non-Current Provisions And Other Non-Current Liabilities - Disclosure of Remeasurement of Net Defined Benefit Liability Asset (Details) - EUR (€) € in Millions	6 Months Ended				12 Months Ended
	Jun. 30, 2024		Jun. 30, 2023		Dec. 31, 2023
Actuarial assumption of discount rates \| Minimum
Disclosure of net defined benefit liability (asset) [Line Items]
Decrease in actuarial assumption	0.40%
Increase in actuarial assumption			(0.15%)
Actuarial assumption of discount rates \| Maximum
Disclosure of net defined benefit liability (asset) [Line Items]
Increase in actuarial assumption	0.65%		0.40%
Eurozone \| Actuarial assumption of expected rates of inflation
Disclosure of net defined benefit liability (asset) [Line Items]
Increase in actuarial assumption			(0.10%)
UKZONE \| Actuarial assumption of expected rates of inflation
Disclosure of net defined benefit liability (asset) [Line Items]
Increase in actuarial assumption	0.10%
Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [Line Items]
Actuarial gains/(losses) on benefit obligations	€ 373	[1]	€ 99	[2]	€ 379
Plan assets \| Pensions and other post-employment benefits
Disclosure of net defined benefit liability (asset) [Line Items]
Actuarial gains/(losses) on plan assets	€ (138)		€ 34		€ (208)

[1] Includes the effects of (i) the change in discount rates (in a range between +0.40% and +0.65%) and (ii) the change in the inflation rate in the United Kingdom (+0.10%) in the first half of 2024. Includes the effects of (i) the change in discount rates (in a range between -0.15% and +0.40%) and (ii) the change in the inflation rate in the eurozone (-0.10%) in the first half of 2023.

Off Balance Sheet Commitments (

Off Balance Sheet Commitments (Details) - USD ($) $ in Millions	May 13, 2024	May 10, 2024
Novavax
Disclosure Of Off Balance Sheet Commitments [Line Items]
Upfront payment		$ 500
Total Milestone Payments		1,200
Development Regulatory And Launch Milestone Payments		700
Additional Launch And Sales Milestone Payments		$ 200
Fulcrum Therapeutics
Disclosure Of Off Balance Sheet Commitments [Line Items]
Upfront payment	$ 80
Contingent Milestone Payments	$ 975

Litigation and Arbitration Pr_2

Litigation and Arbitration Proceedings (Details) - Action for which we are defendant $ in Millions	1 Months Ended
	May 21, 2024 USD ($)	Jun. 30, 2024 proceeding
Plavix Attorney General action in Hawaii
Disclosure of Legal and Arbitral Proceedings [Line Items]
Global penalty fee incurred by defendants, amount vacated \| $	$ 916
Penalty Fee Incurred \| $	$ 458
Taxotere Product Litigation In The US \| Product Liabilities
Disclosure of Legal and Arbitral Proceedings [Line Items]
Number Of Plaintiffs		6,770
Zantac Product Litigation in the US \| Product Liabilities
Disclosure of Legal and Arbitral Proceedings [Line Items]
Number Of Cases		4,400
Gold Bond Product Litigation In The US \| Product Liabilities
Disclosure of Legal and Arbitral Proceedings [Line Items]
Number Of Class Action Lawsuits		600

Other Operating Income And Ex_3

Other Operating Income And Expenses - Additional Information (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	€ 617	€ 617	€ 1,292
Other operating expense	2,010	1,422	3,516
Regeneron \| Other operating income (expense)
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	96	102	€ 227
Other related parties \| Other operating income (expense)
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	118	160
Gains on divestment of some mature products	€ 389	€ 413

Other Operating Income And Ex_4

Other Operating Income And Expenses - Schedule of Other Operating Expenses (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses	€ (2,010)	€ (1,422)	€ (3,516)
Other operating income	617	617	1,292
Other operating income/(expenses), net related to Regeneron	(1,745)	(1,321)	(2,979)
Other related parties \| Other operating income (expense)
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	118	160
Monoclonal Antibodies Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses	(1,837)	(1,418)	(3,196)
Monoclonal Antibodies Alliance \| Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses	(1,934)	(1,449)	(3,321)
Monoclonal Antibodies Alliance \| Additional share of profit paid by Regeneron towards development costs
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	389	291	668
Monoclonal Antibodies Alliance \| Reimbursement to Regeneron of selling expenses incurred
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses	(292)	(260)	(543)
Other (mainly Zaltrap and Libtayo)
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income and expenses	92	97	217
Regeneron \| Other operating income (expense)
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating income	96	102	€ 227
Regeneron \| Other related parties \| Reimbursement to Regeneron of selling expenses incurred
Disclosure Of Other Operating Income Expenses [Line Items]
Other operating expenses	€ (1,841)	€ (1,423)

Restructuring Costs and Simil_3

Restructuring Costs and Similar Items - Summary of Restructuring Costs and Similar Items (Details) - EUR (€) € in Millions		6 Months Ended		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Analysis of income and expense [abstract]
Employee-related expenses		€ 849	€ 185	€ 489
Charges, gains or losses on assets	[1]	(31)	86	293
Costs of transformation programs		347	265	676
Other restructuring costs		166	11	32
Total		€ 1,331	€ 547	€ 1,490

[1](a) This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi

Restructuring Costs and Simil_4

Restructuring Costs and Similar Items - Additional Information (Details) € in Millions	12 Months Ended
	Jun. 30, 2023 EUR (€)
Analysis of income and expense [abstract]
Decrease in total expense of restructuring activities	€ 784

Other Gains and Losses, and L_2

Other Gains and Losses, and Litigation (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Analysis of income and expense [abstract]
Other gains and litigation	€ 442	€ 73	€ 38

Financial Expenses and Income_2

Financial Expenses and Income (Details) - EUR (€) € in Millions		6 Months Ended		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disclosure of detailed information about finance income expense [Line Items]
Cost of debt	[1]	€ (309)	€ (232)	€ (555)
Interest income	[2]	243	257	533
Cost of net debt		(66)	25	(22)
Non-operating foreign exchange gains/(losses)		1	(3)	(2)
Unwinding of discounting of provisions	[3]	(17)	(22)	(59)
Net interest cost related to employee benefits		(40)	(41)	(73)
Gains/(losses) on disposals of financial assets		0	0	(1)
Net interest expense on lease liabilities		(22)	(21)	(39)
Other	[4]	(161)	(22)	(526)
Net financial income/(expenses)		(305)	(84)	(722)
Financial expenses		(586)	(370)	(1,313)
Financial income		281	286	591
Liability Recognised For Estimated Future Royalties		(176)	(35)	(541)
Interest rate and currency derivatives used to hedge debt
Disclosure of detailed information about finance income expense [Line Items]
Gain on derivatives used to manage debt		(24)	(25)	(67)
Gain on derivatives used to manage cash and cash equivalents		€ (18)	€ (4)	€ (13)

[1] Includes net gain/(loss) on interest rate and currency derivatives used to manage debt: €(24) million in the first half of 2024, €(25) million in the first half of 2023, and €(67) million over the whole of 2023. Includes net gain/(loss) on interest rate and currency derivatives used to manage cash and cash equivalents: €(18) million in the first half of 2024, €(4) million in the first half of 2023, and €(13) million over the whole of 2023. Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note B.12.). Includes a financial expense of €176

Income Tax Expense - Summary of

Income Tax Expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Income taxes paid (refund) [abstract]
Current taxes	€ (1,243)	€ (1,171)	€ (2,560)
Deferred taxes	780	441	958
Total	(463)	(730)	(1,602)
Income before tax and investments accounted for using the equity method	€ 2,739	€ 4,238	€ 7,153

Income Tax Expense - Summary _2

Income Tax Expense - Summary of Difference Between Effective Tax Rate and Standard Corporate Income Tax Rate (Details) - EUR (€) € in Millions		6 Months Ended				12 Months Ended
		Jun. 30, 2024		Jun. 30, 2023		Dec. 31, 2023
Income taxes paid (refund) [abstract]
Standard tax rate applicable in France		25.80%	[1]	25.80%	[1]	25.80%
Difference between the standard French tax rate and the rates applicable to Sanofi	[2]	(14.30%)	[1]	(8.20%)	[1]	(13.60%)
Revisions to tax exposures and settlements of tax disputes		3.20%	[1]	0.50%	[1]	2.70%
Tax Rate Effect Of Reversal Of Temporary Difference On Investments	[3]	0%	[1]	0%	[1]	5.10%
Fair value remeasurement of contingent consideration liabilities		0%	[1]	0%	[1]	0.10%
Other (d)	[4]	2.20%	[1]	(0.80%)	[1]	2.30%
Effective tax rate		16.90%	[1]	17.30%	[1]	22.40%
Current tax expense (income)		€ 1,243		€ 1,171		€ 2,560
Current Tax Expense Related to Pillar Two		€ 52

[1] Rate calculated on the basis of the estimated effective tax rate for the full financial year (see Note A.2.). The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France. In accordance with IAS12, a deferred tax liability was recognised in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Opella business, as announced in October 2023. (d)

Income Tax Expense (Details) -

Income Tax Expense (Details) - Summary of Effective Tax Rate and Standard Corporate Income Tax Rate (Parenthetical) € in Millions	6 Months Ended
	Jun. 30, 2024 EUR (€)
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Current Tax Expense Related to Pillar Two	€ 52

Segment Information - Additiona

Segment Information - Additional Information (Details)	6 Months Ended
Segment Information - Additional Information (Details)	Jun. 30, 2024 segment
Disclosure of operating segments [abstract]
Number of operating segments	2

Segment Information - Summary o

Segment Information - Summary of Net Sales by Segment and Geographical Area (Details) € in Millions	6 Months Ended				12 Months Ended
	Jun. 30, 2024 EUR (€) segment		Jun. 30, 2023 EUR (€)		Dec. 31, 2023 EUR (€)
Disclosure of geographical areas [line items]
Net sales	€ 21,209		€ 20,187		€ 43,070
Number of operating segments \| segment	2
Other revenues	€ 1,289		1,358		3,374
Cost of sales	(6,849)		(6,347)		(14,236)
Research and development expense	(3,423)		(3,193)		(6,728)
Selling, general and administrative expense	(5,260)		(5,182)		(10,692)
Attributable to non-controlling interests	17		26		36
Dupixent
Disclosure of geographical areas [line items]
Net sales	18,378		17,467		37,890
Business operating income	4,931		5,220		11,247
Other revenues	1,257		1,331		3,322
Cost of sales	(5,756)		(5,388)		(12,282)
Research and development expense	(3,331)		(3,082)		(6,509)
Selling, general and administrative expense	(4,260)		(4,248)		(8,868)
Other operating income and expenses	(1,417)		(897)		(2,387)
Share of profit/(loss) from investments accounted for using the equity method	66		48		101
Attributable to non-controlling interests	(6)		(11)		(20)
Dupixent \| Pharma Segment
Disclosure of geographical areas [line items]
Net sales	16,059		15,077
Dupixent \| Pharma Launches
Disclosure of geographical areas [line items]
Net sales	1,295		715
Dupixent \| Dupixent
Disclosure of geographical areas [line items]
Net sales	6,138		4,878
Dupixent \| Total Vaccines
Disclosure of geographical areas [line items]
Net sales	2,319		2,390
Dupixent \| Polio/Pertussis/ Hib Vaccines
Disclosure of geographical areas [line items]
Net sales	1,348		1,428
Dupixent \| Influenza Vaccines
Disclosure of geographical areas [line items]
Net sales	188		162
Dupixent \| Nexviazyme
Disclosure of geographical areas [line items]
Net sales	320		184
Dupixent \| Sarclisa
Disclosure of geographical areas [line items]
Net sales	227		181
Dupixent \| Altuviiio
Disclosure of geographical areas [line items]
Net sales	280		19
Dupixent \| Rezurock
Disclosure of geographical areas [line items]
Net sales	207		141
Dupixent \| Cablivi
Disclosure of geographical areas [line items]
Net sales	113		113
Dupixent \| Xenpozyme
Disclosure of geographical areas [line items]
Net sales	72		38
Dupixent \| Enjaymo
Disclosure of geographical areas [line items]
Net sales	55		33
Dupixent \| Tzield
Disclosure of geographical areas [line items]
Net sales	21		6
Dupixent \| RSV Vaccines
Disclosure of geographical areas [line items]
Net sales	200		0
Dupixent \| Meningitis Travel And Endemic Vaccines
Disclosure of geographical areas [line items]
Net sales	582		569
Opella
Disclosure of geographical areas [line items]
Net sales	2,831		2,720		5,180
Business operating income	739		850		1,438
Other revenues	32		27		52
Cost of sales	(1,077)		(949)		(1,933)
Research and development expense	(92)		(111)		(219)
Selling, general and administrative expense	(1,002)		(936)		(1,828)
Other operating income and expenses	43		100		181
Share of profit/(loss) from investments accounted for using the equity method	9		7		21
Attributable to non-controlling interests	(5)		(8)		(16)
Opella \| Seasonal Symptoms And Pain Relief
Disclosure of geographical areas [line items]
Net sales	1,216		1,261
Opella \| Wellness Brands
Disclosure of geographical areas [line items]
Net sales	1,258		1,112
Opella \| Others
Disclosure of geographical areas [line items]
Net sales	357		347
Other segment
Disclosure of geographical areas [line items]
Net sales	0	[1]	0	[2]	0	[3]
Business operating income	(14)	[1]	(11)	[2]	(15)	[3]
Other revenues	0	[1]	0	[2]	0	[3]
Cost of sales	3	[1]	(5)	[2]	(1)	[3]
Research and development expense	0	[1]	0	[2]	0	[3]
Selling, general and administrative expense	2	[1]	2	[2]	4	[3]
Other operating income and expenses	(19)	[1]	(8)	[2]	(18)	[3]
Share of profit/(loss) from investments accounted for using the equity method	0	[1]	0	[2]	0	[3]
Attributable to non-controlling interests	0	[1]	0	[2]	0	[3]
Other Products Segment \| Other Products Segment
Disclosure of geographical areas [line items]
Net sales	8,626		9,484
Other Products Segment \| of which
Disclosure of geographical areas [line items]
Net sales	278		280
Europe
Disclosure of geographical areas [line items]
Net sales	4,882		5,034		10,392
Europe \| Dupixent
Disclosure of geographical areas [line items]
Net sales	4,074		4,194
Europe \| Dupixent \| Pharma Segment
Disclosure of geographical areas [line items]
Net sales	3,692		3,624
Europe \| Dupixent \| Pharma Launches
Disclosure of geographical areas [line items]
Net sales	249		168
Europe \| Dupixent \| Dupixent
Disclosure of geographical areas [line items]
Net sales	770		587
Europe \| Dupixent \| Total Vaccines
Disclosure of geographical areas [line items]
Net sales	382		570
Europe \| Dupixent \| Polio/Pertussis/ Hib Vaccines
Disclosure of geographical areas [line items]
Net sales	248		231
Europe \| Dupixent \| Influenza Vaccines
Disclosure of geographical areas [line items]
Net sales	30		37
Europe \| Dupixent \| Nexviazyme
Disclosure of geographical areas [line items]
Net sales	95		42
Europe \| Dupixent \| Sarclisa
Disclosure of geographical areas [line items]
Net sales	64		56
Europe \| Dupixent \| Altuviiio
Disclosure of geographical areas [line items]
Net sales	0		0
Europe \| Dupixent \| Rezurock
Disclosure of geographical areas [line items]
Net sales	12		2
Europe \| Dupixent \| Cablivi
Disclosure of geographical areas [line items]
Net sales	43		49
Europe \| Dupixent \| Xenpozyme
Disclosure of geographical areas [line items]
Net sales	24		15
Europe \| Dupixent \| Enjaymo
Disclosure of geographical areas [line items]
Net sales	10		4
Europe \| Dupixent \| Tzield
Disclosure of geographical areas [line items]
Net sales	1		0
Europe \| Dupixent \| RSV Vaccines
Disclosure of geographical areas [line items]
Net sales	7		0
Europe \| Dupixent \| Meningitis Travel And Endemic Vaccines
Disclosure of geographical areas [line items]
Net sales	97		72
Europe \| Opella
Disclosure of geographical areas [line items]
Net sales	808		840
Europe \| Other Products Segment \| Other Products Segment
Disclosure of geographical areas [line items]
Net sales	2,673		2,869
Europe \| Other Products Segment \| of which
Disclosure of geographical areas [line items]
Net sales	274		264
United States
Disclosure of geographical areas [line items]
Net sales	9,067		7,988		€ 18,512
United States \| Dupixent
Disclosure of geographical areas [line items]
Net sales	8,294		7,366
United States \| Dupixent \| Pharma Segment
Disclosure of geographical areas [line items]
Net sales	7,550		6,709
United States \| Dupixent \| Pharma Launches
Disclosure of geographical areas [line items]
Net sales	868		460
United States \| Dupixent \| Dupixent
Disclosure of geographical areas [line items]
Net sales	4,437		3,682
United States \| Dupixent \| Total Vaccines
Disclosure of geographical areas [line items]
Net sales	744		657
United States \| Dupixent \| Polio/Pertussis/ Hib Vaccines
Disclosure of geographical areas [line items]
Net sales	311		347
United States \| Dupixent \| Influenza Vaccines
Disclosure of geographical areas [line items]
Net sales	16		19
United States \| Dupixent \| Nexviazyme
Disclosure of geographical areas [line items]
Net sales	174		123
United States \| Dupixent \| Sarclisa
Disclosure of geographical areas [line items]
Net sales	100		76
United States \| Dupixent \| Altuviiio
Disclosure of geographical areas [line items]
Net sales	259		17
United States \| Dupixent \| Rezurock
Disclosure of geographical areas [line items]
Net sales	188		140
United States \| Dupixent \| Cablivi
Disclosure of geographical areas [line items]
Net sales	60		58
United States \| Dupixent \| Xenpozyme
Disclosure of geographical areas [line items]
Net sales	37		21
United States \| Dupixent \| Enjaymo
Disclosure of geographical areas [line items]
Net sales	30		19
United States \| Dupixent \| Tzield
Disclosure of geographical areas [line items]
Net sales	20		6
United States \| Dupixent \| RSV Vaccines
Disclosure of geographical areas [line items]
Net sales	116		0
United States \| Dupixent \| Meningitis Travel And Endemic Vaccines
Disclosure of geographical areas [line items]
Net sales	301		291
United States \| Opella
Disclosure of geographical areas [line items]
Net sales	773		622
United States \| Other Products Segment \| Other Products Segment
Disclosure of geographical areas [line items]
Net sales	2,245		2,567
United States \| Other Products Segment \| of which
Disclosure of geographical areas [line items]
Net sales	3		3
Other countries
Disclosure of geographical areas [line items]
Net sales	7,260		7,165
Other countries \| Dupixent
Disclosure of geographical areas [line items]
Net sales	6,010		5,907
Other countries \| Dupixent \| Pharma Segment
Disclosure of geographical areas [line items]
Net sales	4,817		4,744
Other countries \| Dupixent \| Pharma Launches
Disclosure of geographical areas [line items]
Net sales	178		87
Other countries \| Dupixent \| Dupixent
Disclosure of geographical areas [line items]
Net sales	931		609
Other countries \| Dupixent \| Total Vaccines
Disclosure of geographical areas [line items]
Net sales	1,193		1,163
Other countries \| Dupixent \| Polio/Pertussis/ Hib Vaccines
Disclosure of geographical areas [line items]
Net sales	789		850
Other countries \| Dupixent \| Influenza Vaccines
Disclosure of geographical areas [line items]
Net sales	142		106
Other countries \| Dupixent \| Nexviazyme
Disclosure of geographical areas [line items]
Net sales	51		19
Other countries \| Dupixent \| Sarclisa
Disclosure of geographical areas [line items]
Net sales	63		49
Other countries \| Dupixent \| Altuviiio
Disclosure of geographical areas [line items]
Net sales	21		2
Other countries \| Dupixent \| Rezurock
Disclosure of geographical areas [line items]
Net sales	7		(1)
Other countries \| Dupixent \| Cablivi
Disclosure of geographical areas [line items]
Net sales	10		6
Other countries \| Dupixent \| Xenpozyme
Disclosure of geographical areas [line items]
Net sales	11		2
Other countries \| Dupixent \| Enjaymo
Disclosure of geographical areas [line items]
Net sales	15		10
Other countries \| Dupixent \| Tzield
Disclosure of geographical areas [line items]
Net sales			0
Other countries \| Dupixent \| RSV Vaccines
Disclosure of geographical areas [line items]
Net sales	77		0
Other countries \| Dupixent \| Meningitis Travel And Endemic Vaccines
Disclosure of geographical areas [line items]
Net sales	184		206
Other countries \| Opella
Disclosure of geographical areas [line items]
Net sales	1,250		1,258
Other countries \| Other Products Segment \| Other Products Segment
Disclosure of geographical areas [line items]
Net sales	3,708		4,048
Other countries \| Other Products Segment \| of which
Disclosure of geographical areas [line items]
Net sales	€ 1		€ 13

[1] (a) The “Other” column reconciles segmental results to the total per the consolidated financial statements. (a) The “Other” column reconciles segmental results to the total per the consolidated financial statements. (a) The “Other” column reconciles segmental results to the total per the consolidated financial statements.

Segment Information - Schedule

Segment Information - Schedule of Segment Results (Details) € in Millions	6 Months Ended				12 Months Ended
	Jun. 30, 2024 EUR (€) segment		Jun. 30, 2023 EUR (€)		Dec. 31, 2023 EUR (€)
Disclosure of operating segments [Line Items]
Net sales	€ 21,209		€ 20,187		€ 43,070
Other revenues	1,289		1,358		3,374
Cost of sales	(6,849)		(6,347)		(14,236)
Research and development expenses	(3,423)		(3,193)		(6,728)
Selling and general expenses	(5,260)		(5,182)		(10,692)
Net income attributable to non-controlling interests	€ 17		26		36
Number of operating segments \| segment	2
Total
Disclosure of operating segments [Line Items]
Net sales	€ 21,209		20,187		43,070
Other revenues	1,289		1,358		3,374
Cost of sales	(6,830)		(6,342)		(14,216)
Research and development expenses	(3,423)		(3,193)		(6,728)
Selling and general expenses	(5,260)		(5,182)		(10,692)
Other operating income and expenses	(1,393)		(805)		(2,224)
Share of profit/(loss) from investments accounted for using the equity method	75		55		122
Net income attributable to non-controlling interests	(11)		(19)		(36)
Business operating income	5,656		6,059		12,670
Dupixent
Disclosure of operating segments [Line Items]
Net sales	18,378		17,467		37,890
Other revenues	1,257		1,331		3,322
Cost of sales	(5,756)		(5,388)		(12,282)
Research and development expenses	(3,331)		(3,082)		(6,509)
Selling and general expenses	(4,260)		(4,248)		(8,868)
Other operating income and expenses	(1,417)		(897)		(2,387)
Share of profit/(loss) from investments accounted for using the equity method	66		48		101
Net income attributable to non-controlling interests	(6)		(11)		(20)
Business operating income	4,931		5,220		11,247
Other
Disclosure of operating segments [Line Items]
Net sales	0	[1]	0	[2]	0	[3]
Other revenues	0	[1]	0	[2]	0	[3]
Cost of sales	3	[1]	(5)	[2]	(1)	[3]
Research and development expenses	0	[1]	0	[2]	0	[3]
Selling and general expenses	2	[1]	2	[2]	4	[3]
Other operating income and expenses	(19)	[1]	(8)	[2]	(18)	[3]
Share of profit/(loss) from investments accounted for using the equity method	0	[1]	0	[2]	0	[3]
Net income attributable to non-controlling interests	0	[1]	0	[2]	0	[3]
Business operating income	€ (14)	[1]	€ (11)	[2]	€ (15)	[3]

[1] (a) The “Other” column reconciles segmental results to the total per the consolidated financial statements. (a) The “Other” column reconciles segmental results to the total per the consolidated financial statements. (a) The “Other” column reconciles segmental results to the total per the consolidated financial statements.

Segment Information - Schedul_2

Segment Information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details) - EUR (€) € in Millions		6 Months Ended		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disclosure of operating segments [Line Items]
Net income attributable to non-controlling interests		€ 17	€ 26	€ 36
Fair value remeasurement of contingent consideration		(66)	(26)	(93)
Restructuring costs and similar items		(1,331)	(547)	(1,490)
Other gains and losses, and litigation		(442)	(73)	(38)
Operating income		3,044	4,322	7,875
Financial expenses		(586)	(370)	(1,313)
Financial income		281	286	591
Income before tax and investments accounted for using the equity method		2,739	4,238	7,153
Impairment loss on other intangible assets		(371)	15	896
Net Reversal of Impairment Loss		371	833
Operating segments
Disclosure of operating segments [Line Items]
Business operating income		5,656	6,059	12,670
Material reconciling items
Disclosure of operating segments [Line Items]
Share of profit/(loss) from investments accounted for using the equity method	[1]	(75)	(55)	(122)
Net income attributable to non-controlling interests	[2]	11	19	36
Amortization and impairment of intangible assets	[3]	(690)	(1,050)	(3,068)
Fair value remeasurement of contingent consideration		(66)	(26)	(93)
Expense arising from the impact of acquisitions on inventories	[4]	(19)	(5)	(20)
Restructuring costs and similar items	[5]	(1,331)	(547)	(1,490)
Other gains and losses, and litigation	[6]	€ (442)	€ (73)	€ (38)

[1] Joint ventures and associates with which Sanofi has entered into a strategic alliance. Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. As of June 30, 2024, this line includes a net reversal of impairment losses amounting to of €371 million, mainly due to an increase in the expected recoverable amounts of certain marketed products and other rights in the Biopharma segment. For 2023, this amount mainly comprises an impairment loss of €833 million, reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms. This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date. See note B.16.

Segment Information - Schedul_3

Segment Information - Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment (Details) € in Millions		6 Months Ended				12 Months Ended
		Jun. 30, 2024 EUR (€) segment		Jun. 30, 2023 EUR (€)		Dec. 31, 2023 EUR (€)
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method		€ 315				€ 424
Number of operating segments \| segment		2
Total
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method		€ 243	[1]	€ 241	[2]	262	[3]
Acquisitions of property, plant and equipment		950		782		1,719
Acquisitions of other intangible assets		936		148		1,305
Dupixent
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method		229	[1]	231	[2]	234	[3]
Acquisitions of property, plant and equipment		882		751		1,619
Acquisitions of other intangible assets		922		132		1,287
Opella
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method	[2]			10
Acquisitions of property, plant and equipment				31
Acquisitions of other intangible assets				€ 16
Opella
Disclosure of operating segments [Line Items]
Investments accounted for using the equity method		14	[1]			28	[3]
Acquisitions of property, plant and equipment		68				100
Acquisitions of other intangible assets		€ 14				€ 18

[1] (a) Carrying amount at the end of the reporting period. (a) Carrying amount at the end of the reporting period. (a) Carrying amount at the end of the reporting period.

Segment Information - Summary_2

Segment Information - Summary of Geographical Information on Net Sales and Non-Current Assets (Details) - EUR (€) € in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disclosure of geographical areas [line items]
Net sales	€ 21,209	€ 20,187	€ 43,070
Non-current assets:
property, plant and equipment	10,264		10,160
Goodwill	50,080		49,404
Other intangible assets	26,653		24,319
Total
Disclosure of geographical areas [line items]
Net sales	21,209	20,187	43,070
Non-current assets:
property, plant and equipment	10,264	9,804	10,160
Goodwill	50,080	49,243	49,404
Other intangible assets	26,653	24,590	24,319
Europe
Disclosure of geographical areas [line items]
Net sales	4,882	5,034	10,392
Non-current assets:
property, plant and equipment	5,611	5,462	5,659
Goodwill	0	0	0
Other intangible assets	5,156	5,961	5,566
France
Disclosure of geographical areas [line items]
Net sales	1,082	1,174	2,379
Non-current assets:
property, plant and equipment	3,079	2,921	3,085
Goodwill	0	0	0
Other intangible assets	0	0	0
United States
Disclosure of geographical areas [line items]
Net sales	9,067	7,988	18,512
Non-current assets:
property, plant and equipment	2,377	2,364	2,322
Goodwill	0	0	0
Other intangible assets	20,726	17,595	17,850
Other countries
Disclosure of geographical areas [line items]
Net sales	7,260	7,165	14,166
Non-current assets:
property, plant and equipment	2,276	1,978	2,179
Goodwill	0	0	0
Other intangible assets	€ 771	€ 1,034	€ 903

Segment Information - Principal

Segment Information - Principal Customers and Credit Risk (Details)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Certain wholesalers in the United States
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue	29%
Customer one
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue	13%	11%
Customer two
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue	9%	9%
Customer three
Disclosure of information about major customers and credit risk [line items]
Percentage of entity's revenue	7%	7%

Uncategorized Items - _IXDS

Label	Element	Value
Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares	sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares	€ 0
Treasury shares [member]
Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares	sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares	3,000,000
Issued capital [member]
Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares	sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares	0
Retained earnings [member]
Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares	sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares	(3,000,000)
Additional paid-in capital [member]
Increase (Decrease) Through Share-Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares	sny_IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares	0
Other intangible assets [member]
Impairment Loss on Intangible Asset Other Than Goodwill	sny_ImpairmentLossOnIntangibleAssetOtherThanGoodwill	€ 366,000,000